<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36543887</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>07</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-1784</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Nature reviews. Drug discovery</Title><ISOAbbreviation>Nat Rev Drug Discov</ISOAbbreviation></Journal><ArticleTitle>Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation.</ArticleTitle><Pagination><StartPage>185</StartPage><EndPage>212</EndPage><MedlinePgn>185-212</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41573-022-00612-2</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a devastating disease caused by degeneration of motor neurons. As with all major neurodegenerative disorders, development of disease-modifying therapies has proven challenging for multiple reasons. Nevertheless, ALS is one of the few neurodegenerative diseases for which disease-modifying therapies are approved. Significant discoveries and advances have been made in ALS preclinical models, genetics, pathology, biomarkers, imaging and clinical readouts over the last 10-15 years. At the same time, novel therapeutic paradigms are being applied in areas of high unmet medical need, including neurodegenerative disorders. These developments have evolved our knowledge base, allowing identification of targeted candidate therapies for ALS with diverse mechanisms of action. In this Review, we discuss how this advanced knowledge, aligned with new approaches, can enable effective translation of therapeutic agents from preclinical studies through to clinical benefit for patients with ALS. We anticipate that this approach in ALS will also positively impact the field of drug discovery for neurodegenerative disorders more broadly.</AbstractText><CopyrightInformation>&#xa9; 2022. Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mead</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials><Identifier Source="ORCID">0000-0002-3207-0068</Identifier><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Institute, University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Keapstone Therapeutics, The Innovation Centre, Broomhall, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shan</LastName><ForeName>Ning</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Aclipse Therapeutics, Radnor, PA, US.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reiser</LastName><ForeName>H Joseph</ForeName><Initials>HJ</Initials><Identifier Source="ORCID">0000-0001-5728-2879</Identifier><AffiliationInfo><Affiliation>Aclipse Therapeutics, Radnor, PA, US.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marshall</LastName><ForeName>Fiona</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-8681-005X</Identifier><AffiliationInfo><Affiliation>MSD UK Discovery Centre, Merck, Sharp and Dohme (UK) Limited, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Pamela J</ForeName><Initials>PJ</Initials><Identifier Source="ORCID">0000-0002-8925-2567</Identifier><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience, Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, UK. pamela.shaw@sheffield.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Institute, University of Sheffield, Sheffield, UK. pamela.shaw@sheffield.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Keapstone Therapeutics, The Innovation Centre, Broomhall, Sheffield, UK. pamela.shaw@sheffield.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/V027735/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Rev Drug Discov</MedlineTA><NlmUniqueID>101124171</NlmUniqueID><ISSNLinking>1474-1776</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055808" MajorTopicYN="N">Drug Discovery</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>R.J.M. is cofounder of and holds shares in Keapstone Therapeutics, collaborates and receives funding from BenevolentAI, Quell Therapeutics, Sosei&#xa0;Heptares and MSD, is a consultant to Aclipse Therapeutics, has shares in Aclipse One Inc and is an inventor on patents related to M102. N.S. is an employee and shareholder of Aclipse Therapeutics. H.J.R. is the chairman of the Board of Aclipse Therapeutics. F.M. is an employee and shareholder of Merck and Co. P.J.S. is an advisory board member and consultant for Biogen, Aclipse Therapeutics, Quell Therapeutics, BenevolentAI, QurAlis, Astex, GeniUS and Eli Lilly and collaborates with and receives research funding from Quell Therapeutics, Aclipse Therapeutics, Pfizer and SwanBio. She is a cofounder of and holds shares in Keapstone Therapeutics and holds shares in Aclipse One Inc. She is an inventor on patents related to low-dose IL-2, SRSF1 and M102. Support for clinical trials participation in the last five years has been received from Biogen, Alexion, Orion Pharma, WAVE, the EU Horizon 2020 programme and UK NIHR.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>21</Day><Hour>23</Hour><Minute>29</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36543887</ArticleId><ArticleId IdType="pmc">PMC9768794</ArticleId><ArticleId IdType="doi">10.1038/s41573-022-00612-2</ArticleId><ArticleId IdType="pii">10.1038/s41573-022-00612-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Longinetti E, Fang F. Epidemiology of amyotrophic lateral sclerosis: an update of recent literature. Curr. Opin. Neurol. 2019;32:771&#x2013;776. doi: 10.1097/WCO.0000000000000730.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000730</ArticleId><ArticleId IdType="pmc">PMC6735526</ArticleId><ArticleId IdType="pubmed">31361627</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown CA, Lally C, Kupelian V, Flanders WD. Estimated prevalence and incidence of amyotrophic lateral sclerosis and SOD1 and C9orf72 genetic variants. Neuroepidemiology. 2021;55:342&#x2013;353. doi: 10.1159/000516752.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000516752</ArticleId><ArticleId IdType="pubmed">34247168</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan M, Heverin M, McLaughlin RL, Hardiman O. Lifetime risk and heritability of amyotrophic lateral sclerosis. JAMA Neurol. 2019;76:1367&#x2013;1374. doi: 10.1001/jamaneurol.2019.2044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.2044</ArticleId><ArticleId IdType="pmc">PMC6646974</ArticleId><ArticleId IdType="pubmed">31329211</ArticleId></ArticleIdList></Reference><Reference><Citation>GBD 2016 Motor Neuron Disease Collaborators. Global, regional, and national burden of motor neuron diseases 1990&#x2013;2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17:1083&#x2013;1097. doi: 10.1016/S1474-4422(18)30404-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30404-6</ArticleId><ArticleId IdType="pmc">PMC6234315</ArticleId><ArticleId IdType="pubmed">30409709</ArticleId></ArticleIdList></Reference><Reference><Citation>Masrori P, Van Damme P. Amyotrophic lateral sclerosis: a clinical review. Eur. J. Neurol. 2020;27:1918&#x2013;1929. doi: 10.1111/ene.14393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14393</ArticleId><ArticleId IdType="pmc">PMC7540334</ArticleId><ArticleId IdType="pubmed">32526057</ArticleId></ArticleIdList></Reference><Reference><Citation>Elamin M, et al. Cognitive changes predict functional decline in ALS: a population-based longitudinal study. Neurology. 2013;80:1590&#x2013;1597. doi: 10.1212/WNL.0b013e31828f18ac.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31828f18ac</ArticleId><ArticleId IdType="pubmed">23553481</ArticleId></ArticleIdList></Reference><Reference><Citation>Phukan J, et al. The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study. J. Neurol. Neurosurg. Psychiatry. 2012;83:102&#x2013;108. doi: 10.1136/jnnp-2011-300188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2011-300188</ArticleId><ArticleId IdType="pubmed">21836033</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling SC, Polymenidou M, Cleveland DW. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron. 2013;79:416&#x2013;438. doi: 10.1016/j.neuron.2013.07.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.07.033</ArticleId><ArticleId IdType="pmc">PMC4411085</ArticleId><ArticleId IdType="pubmed">23931993</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan RH, Ke YD, Ittner LM, Halliday GM. ALS/FTLD: experimental models and reality. Acta Neuropathol. 2017;133:177&#x2013;196. doi: 10.1007/s00401-016-1666-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1666-6</ArticleId><ArticleId IdType="pubmed">28058507</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, et al. Amyotrophic lateral sclerosis. Nat. Rev. Dis. Prim. 2017;3:17085. doi: 10.1038/nrdp.2017.85.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.85</ArticleId><ArticleId IdType="pubmed">29052611</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann. Neurol. 2007;61:427&#x2013;434. doi: 10.1002/ana.21147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21147</ArticleId><ArticleId IdType="pubmed">17469116</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323:1208&#x2013;1211. doi: 10.1126/science.1165942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1165942</ArticleId><ArticleId IdType="pmc">PMC4516382</ArticleId><ArticleId IdType="pubmed">19251628</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato S, et al. Copper chaperone for superoxide dismutase co-aggregates with superoxide dismutase 1 (SOD1) in neuronal Lewy body-like hyaline inclusions: an immunohistochemical study on familial amyotrophic lateral sclerosis with SOD1 gene mutation. Acta Neuropathol. 2001;102:233&#x2013;238. doi: 10.1007/s004010000355.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s004010000355</ArticleId><ArticleId IdType="pubmed">11585247</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos-Campoy O, et al. Systematic screening of ubiquitin/p62 aggregates in cerebellar cortex expands the neuropathological phenotype of the C9orf72 expansion mutation. J. Neuropathol. Exp. Neurol. 2018;77:703&#x2013;709. doi: 10.1093/jnen/nly047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/nly047</ArticleId><ArticleId IdType="pubmed">29889265</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Talbot K. Mimics and chameleons in motor neurone disease. Pract. Neurol. 2013;13:153&#x2013;164. doi: 10.1136/practneurol-2013-000557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/practneurol-2013-000557</ArticleId><ArticleId IdType="pmc">PMC3664389</ArticleId><ArticleId IdType="pubmed">23616620</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Mot. Neuron Disord. 2000;1:293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M, et al. Electrodiagnostic criteria for diagnosis of ALS. Clin. Neurophysiol. 2008;119:497&#x2013;503. doi: 10.1016/j.clinph.2007.09.143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2007.09.143</ArticleId><ArticleId IdType="pubmed">18164242</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, et al. A proposal for new diagnostic criteria for ALS. Clin. Neurophysiol. 2020;131:1975&#x2013;1978. doi: 10.1016/j.clinph.2020.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2020.04.005</ArticleId><ArticleId IdType="pubmed">32387049</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrov D, Mansfield C, Moussy A, Hermine O. ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment? Front. Aging Neurosci. 2017;9:68. doi: 10.3389/fnagi.2017.00068.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00068</ArticleId><ArticleId IdType="pmc">PMC5360725</ArticleId><ArticleId IdType="pubmed">28382000</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacomblez L, et al. A confirmatory dose-ranging study of riluzole in ALS. ALS/Riluzole Study Group-II. Neurology. 1996;47:S242&#x2013;S250. doi: 10.1212/WNL.47.6_Suppl_4.242S.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.47.6_Suppl_4.242S</ArticleId><ArticleId IdType="pubmed">8959996</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet. 1996;347:1425&#x2013;1431. doi: 10.1016/S0140-6736(96)91680-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(96)91680-3</ArticleId><ArticleId IdType="pubmed">8676624</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N. Engl. J. Med. 1994;330:585&#x2013;591. doi: 10.1056/NEJM199403033300901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199403033300901</ArticleId><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Kretschmer BD, Kratzer U, Schmidt WJ. Riluzole, a glutamate release inhibitor, and motor behavior. Naunyn Schmiedebergs Arch. Pharmacol. 1998;358:181&#x2013;190. doi: 10.1007/PL00005241.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/PL00005241</ArticleId><ArticleId IdType="pubmed">9750003</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SJ, Wang KY, Wang WC. Mechanisms underlying the riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes) Neuroscience. 2004;125:191&#x2013;201. doi: 10.1016/j.neuroscience.2004.01.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2004.01.019</ArticleId><ArticleId IdType="pubmed">15051158</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews JA, et al. Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Frontotemporal Degener. 2020;21:509&#x2013;518. doi: 10.1080/21678421.2020.1771734.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1771734</ArticleId><ArticleId IdType="pubmed">32573277</ArticleId></ArticleIdList></Reference><Reference><Citation>The Writing Group on behalf of the Edaravone (MCI-186) ALS 19 Study Group Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505&#x2013;512. doi: 10.1016/S1474-4422(17)30115-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawada H. Clinical efficacy of edaravone for the treatment of amyotrophic lateral sclerosis. Expert. Opin. Pharmacother. 2017;18:735&#x2013;738. doi: 10.1080/14656566.2017.1319937.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14656566.2017.1319937</ArticleId><ArticleId IdType="pubmed">28406335</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourke SC, et al. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol. 2006;5:140&#x2013;147. doi: 10.1016/S1474-4422(05)70326-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(05)70326-4</ArticleId><ArticleId IdType="pubmed">16426990</ArticleId></ArticleIdList></Reference><Reference><Citation>Lechtzin N, et al. Early use of non-invasive ventilation prolongs survival in subjects with ALS. Amyotroph. Lateral Scler. 2007;8:185&#x2013;188. doi: 10.1080/17482960701262392.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960701262392</ArticleId><ArticleId IdType="pubmed">17538782</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59&#x2013;62. doi: 10.1038/362059a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/362059a0</ArticleId><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranganathan R, et al. Multifaceted genes in amyotrophic lateral sclerosis-frontotemporal dementia. Front. Neurosci. 2020;14:684. doi: 10.3389/fnins.2020.00684.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.00684</ArticleId><ArticleId IdType="pmc">PMC7358438</ArticleId><ArticleId IdType="pubmed">32733193</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rheenen W, et al. Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nat. Genet. 2021;53:1636&#x2013;1648. doi: 10.1038/s41588-021-00973-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-021-00973-1</ArticleId><ArticleId IdType="pmc">PMC8648564</ArticleId><ArticleId IdType="pubmed">34873335</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rheenen W, et al. Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nat. Genet. 2016;48:1043&#x2013;1048. doi: 10.1038/ng.3622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3622</ArticleId><ArticleId IdType="pmc">PMC5556360</ArticleId><ArticleId IdType="pubmed">27455348</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepheard SR, et al. Value of systematic genetic screening of patients with amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2021;92:510&#x2013;518. doi: 10.1136/jnnp-2020-325014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-325014</ArticleId><ArticleId IdType="pmc">PMC8053339</ArticleId><ArticleId IdType="pubmed">33589474</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S, et al. Genome-wide identification of the genetic basis of amyotrophic lateral sclerosis. Neuron. 2022;110:992&#x2013;1008.e11. doi: 10.1016/j.neuron.2021.12.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2021.12.019</ArticleId><ArticleId IdType="pmc">PMC9017397</ArticleId><ArticleId IdType="pubmed">35045337</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, et al. Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Lancet Neurol. 2014;13:1108&#x2013;1113. doi: 10.1016/S1474-4422(14)70219-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70219-4</ArticleId><ArticleId IdType="pmc">PMC4197338</ArticleId><ArticleId IdType="pubmed">25300936</ArticleId></ArticleIdList></Reference><Reference><Citation>Julian TH, et al. A review of Mendelian randomization in amyotrophic lateral sclerosis. Brain. 2021;145:832&#x2013;842. doi: 10.1093/brain/awab420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab420</ArticleId><ArticleId IdType="pmc">PMC9050546</ArticleId><ArticleId IdType="pubmed">34791088</ArticleId></ArticleIdList></Reference><Reference><Citation>Julian TH, et al. Physical exercise is a risk factor for amyotrophic lateral sclerosis: convergent evidence from Mendelian randomisation, transcriptomics and risk genotypes. EBioMedicine. 2021;68:103397. doi: 10.1016/j.ebiom.2021.103397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103397</ArticleId><ArticleId IdType="pmc">PMC8170114</ArticleId><ArticleId IdType="pubmed">34051439</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandres-Ciga S, et al. Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Ann. Neurol. 2019;85:470&#x2013;481. doi: 10.1002/ana.25431.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25431</ArticleId><ArticleId IdType="pmc">PMC6450729</ArticleId><ArticleId IdType="pubmed">30723964</ArticleId></ArticleIdList></Reference><Reference><Citation>McKay KA, et al. Military service and related risk factors for amyotrophic lateral sclerosis. Acta Neurol. Scand. 2021;143:39&#x2013;50. doi: 10.1111/ane.13345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ane.13345</ArticleId><ArticleId IdType="pmc">PMC7756624</ArticleId><ArticleId IdType="pubmed">32905613</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingre C, Roos PM, Piehl F, Kamel F, Fang F. Risk factors for amyotrophic lateral sclerosis. Clin. Epidemiol. 2015;7:181&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4334292</ArticleId><ArticleId IdType="pubmed">25709501</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacorte E, et al. Physical activity, and physical activity related to sports, leisure and occupational activity as risk factors for ALS: a systematic review. Neurosci. Biobehav. Rev. 2016;66:61&#x2013;79. doi: 10.1016/j.neubiorev.2016.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2016.04.007</ArticleId><ArticleId IdType="pubmed">27108217</ArticleId></ArticleIdList></Reference><Reference><Citation>Armon C. Smoking may be considered an established risk factor for sporadic ALS. Neurology. 2009;73:1693&#x2013;1698. doi: 10.1212/WNL.0b013e3181c1df48.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181c1df48</ArticleId><ArticleId IdType="pmc">PMC2788806</ArticleId><ArticleId IdType="pubmed">19917993</ArticleId></ArticleIdList></Reference><Reference><Citation>Barber SC, Shaw PJ. Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free. Radic. Biol. Med. 2010;48:629&#x2013;641. doi: 10.1016/j.freeradbiomed.2009.11.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2009.11.018</ArticleId><ArticleId IdType="pubmed">19969067</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraiuolo L, Kirby J, Grierson AJ, Sendtner M, Shaw PJ. Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat. Rev. Neurol. 2011;7:616&#x2013;630. doi: 10.1038/nrneurol.2011.152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2011.152</ArticleId><ArticleId IdType="pubmed">22051914</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Amico E, Factor-Litvak P, Santella RM, Mitsumoto H. Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis. Free Radic. Biol. Med. 2013;65:509&#x2013;527. doi: 10.1016/j.freeradbiomed.2013.06.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2013.06.029</ArticleId><ArticleId IdType="pmc">PMC3859834</ArticleId><ArticleId IdType="pubmed">23797033</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto H, et al. Oxidative stress biomarkers in sporadic ALS. Amyotroph. Lateral Scler. 2008;9:177&#x2013;183. doi: 10.1080/17482960801933942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960801933942</ArticleId><ArticleId IdType="pmc">PMC4332387</ArticleId><ArticleId IdType="pubmed">18574762</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K. Glutathione in the nervous system as a potential therapeutic target to control the development and progression of amyotrophic lateral sclerosis. Antioxidants. 2021;10:1011. doi: 10.3390/antiox10071011.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox10071011</ArticleId><ArticleId IdType="pmc">PMC8300718</ArticleId><ArticleId IdType="pubmed">34201812</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuadrado A, et al. Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat. Rev. Drug Discov. 2019;18:295&#x2013;317. doi: 10.1038/s41573-018-0008-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41573-018-0008-x</ArticleId><ArticleId IdType="pubmed">30610225</ArticleId></ArticleIdList></Reference><Reference><Citation>Jimenez-Villegas J, et al. NRF2 as a therapeutic opportunity to impact in the molecular roadmap of ALS. Free Radic. Biol. Med. 2021;173:125&#x2013;141. doi: 10.1016/j.freeradbiomed.2021.07.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2021.07.022</ArticleId><ArticleId IdType="pubmed">34314817</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen TJ, et al. An acetylation switch controls TDP-43 function and aggregation propensity. Nat. Commun. 2015;6:5845. doi: 10.1038/ncomms6845.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms6845</ArticleId><ArticleId IdType="pmc">PMC4407365</ArticleId><ArticleId IdType="pubmed">25556531</ArticleId></ArticleIdList></Reference><Reference><Citation>Colombrita C, et al. TDP-43 is recruited to stress granules in conditions of oxidative insult. J. Neurochem. 2009;111:1051&#x2013;1061. doi: 10.1111/j.1471-4159.2009.06383.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2009.06383.x</ArticleId><ArticleId IdType="pubmed">19765185</ArticleId></ArticleIdList></Reference><Reference><Citation>Goh CW, et al. Chronic oxidative stress promotes GADD34-mediated phosphorylation of the TAR DNA-binding protein TDP-43, a modification linked to neurodegeneration. J. Biol. Chem. 2018;293:163&#x2013;176. doi: 10.1074/jbc.M117.814111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M117.814111</ArticleId><ArticleId IdType="pmc">PMC5766914</ArticleId><ArticleId IdType="pubmed">29109149</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo X, et al. TDP-43 aggregation induced by oxidative stress causes global mitochondrial imbalance in ALS. Nat. Struct. Mol. Biol. 2021;28:132&#x2013;142. doi: 10.1038/s41594-020-00537-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41594-020-00537-7</ArticleId><ArticleId IdType="pubmed">33398173</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazama M, et al. Astrocytes release glutamate via cystine/glutamate antiporter upregulated in response to increased oxidative stress related to sporadic amyotrophic lateral sclerosis. Neuropathology. 2020;40:587&#x2013;598. doi: 10.1111/neup.12716.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/neup.12716</ArticleId><ArticleId IdType="pubmed">33305472</ArticleId></ArticleIdList></Reference><Reference><Citation>Deora V, et al. The microglial NLRP3 inflammasome is activated by amyotrophic lateral sclerosis proteins. Glia. 2020;68:407&#x2013;421. doi: 10.1002/glia.23728.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.23728</ArticleId><ArticleId IdType="pubmed">31596526</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M. Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol. Dis. 2007;26:1&#x2013;13. doi: 10.1016/j.nbd.2006.12.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2006.12.015</ArticleId><ArticleId IdType="pubmed">17300945</ArticleId></ArticleIdList></Reference><Reference><Citation>King AE, Woodhouse A, Kirkcaldie MT, Vickers JC. Excitotoxicity in ALS: overstimulation, or overreaction? Exp. Neurol. 2016;275:162&#x2013;171. doi: 10.1016/j.expneurol.2015.09.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2015.09.019</ArticleId><ArticleId IdType="pubmed">26584004</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme P, Dewil M, Robberecht W, Van Den Bosch L. Excitotoxicity and amyotrophic lateral sclerosis. Neurodegener. Dis. 2005;2:147&#x2013;159. doi: 10.1159/000089620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000089620</ArticleId><ArticleId IdType="pubmed">16909020</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewerenz J, et al. The cystine/glutamate antiporter system xc&#x2212; in health and disease: from molecular mechanisms to novel therapeutic opportunities. Antioxid. Redox Signal. 2013;18:522&#x2013;555. doi: 10.1089/ars.2011.4391.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2011.4391</ArticleId><ArticleId IdType="pmc">PMC3545354</ArticleId><ArticleId IdType="pubmed">22667998</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams TL, Day NC, Ince PG, Kamboj RK, Shaw PJ. Calcium-permeable &#x3b1;-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors: a molecular determinant of selective vulnerability in amyotrophic lateral sclerosis. Ann. Neurol. 1997;42:200&#x2013;207. doi: 10.1002/ana.410420211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410420211</ArticleId><ArticleId IdType="pubmed">9266730</ArticleId></ArticleIdList></Reference><Reference><Citation>Ince P, et al. Parvalbumin and calbindin D-28k in the human motor system and in motor neuron disease. Neuropathol. Appl. Neurobiol. 1993;19:291&#x2013;299. doi: 10.1111/j.1365-2990.1993.tb00443.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2990.1993.tb00443.x</ArticleId><ArticleId IdType="pubmed">8232749</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn LI, et al. ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron. 1997;18:327&#x2013;338. doi: 10.1016/S0896-6273(00)80272-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)80272-X</ArticleId><ArticleId IdType="pubmed">9052802</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauriat TL, McInnes LA. EAAT2 regulation and splicing: relevance to psychiatric and neurological disorders. Mol. Psychiatry. 2007;12:1065&#x2013;1078. doi: 10.1038/sj.mp.4002065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.mp.4002065</ArticleId><ArticleId IdType="pubmed">17684493</ArticleId></ArticleIdList></Reference><Reference><Citation>Pajarillo E, Rizor A, Lee J, Aschner M, Lee E. The role of astrocytic glutamate transporters GLT-1 and GLAST in neurological disorders: potential targets for neurotherapeutics. Neuropharmacology. 2019;161:107559. doi: 10.1016/j.neuropharm.2019.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2019.03.002</ArticleId><ArticleId IdType="pmc">PMC6731169</ArticleId><ArticleId IdType="pubmed">30851309</ArticleId></ArticleIdList></Reference><Reference><Citation>Selvaraj BT, et al. C9ORF72 repeat expansion causes vulnerability of motor neurons to Ca2+-permeable AMPA receptor-mediated excitotoxicity. Nat. Commun. 2018;9:347. doi: 10.1038/s41467-017-02729-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-02729-0</ArticleId><ArticleId IdType="pmc">PMC5783946</ArticleId><ArticleId IdType="pubmed">29367641</ArticleId></ArticleIdList></Reference><Reference><Citation>Dafinca R, et al. Impairment of mitochondrial calcium buffering links mutations in C9ORF72 and TARDBP in iPS-derived motor neurons from patients with ALS/FTD. Stem Cell Rep. 2020;14:892&#x2013;908. doi: 10.1016/j.stemcr.2020.03.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2020.03.023</ArticleId><ArticleId IdType="pmc">PMC7220989</ArticleId><ArticleId IdType="pubmed">32330447</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic S, Pavey N, Haidar M, Turner BJ, Kiernan MC. Cortical hyperexcitability: diagnostic and pathogenic biomarker of ALS. Neurosci. Lett. 2021;759:136039. doi: 10.1016/j.neulet.2021.136039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2021.136039</ArticleId><ArticleId IdType="pubmed">34118310</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamanauskas N, Nistri A. Riluzole blocks persistent Na+ and Ca2+ currents and modulates release of glutamate via presynaptic NMDA receptors on neonatal rat hypoglossal motoneurons in vitro. Eur. J. Neurosci. 2008;27:2501&#x2013;2514. doi: 10.1111/j.1460-9568.2008.06211.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1460-9568.2008.06211.x</ArticleId><ArticleId IdType="pubmed">18445055</ArticleId></ArticleIdList></Reference><Reference><Citation>Dyer AM, Smith A. Riluzole 5&#x2009;mg/mL oral suspension: for optimized drug delivery in amyotrophic lateral sclerosis. Drug. Des. Devel Ther. 2017;11:59&#x2013;64. doi: 10.2147/DDDT.S123776.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DDDT.S123776</ArticleId><ArticleId IdType="pmc">PMC5191840</ArticleId><ArticleId IdType="pubmed">28053507</ArticleId></ArticleIdList></Reference><Reference><Citation>Battaglia G, Bruno V. Metabotropic glutamate receptor involvement in the pathophysiology of amyotrophic lateral sclerosis: new potential drug targets for therapeutic applications. Curr. Opin. Pharmacol. 2018;38:65&#x2013;71. doi: 10.1016/j.coph.2018.02.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coph.2018.02.007</ArticleId><ArticleId IdType="pubmed">29529498</ArticleId></ArticleIdList></Reference><Reference><Citation>Cabral-Costa JV, Kowaltowski AJ. Neurological disorders and mitochondria. Mol. Asp. Med. 2020;71:100826. doi: 10.1016/j.mam.2019.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mam.2019.10.003</ArticleId><ArticleId IdType="pubmed">31630771</ArticleId></ArticleIdList></Reference><Reference><Citation>Jhanji R, Behl T, Sehgal A, Bungau S. Mitochondrial dysfunction and traffic jams in amyotrophic lateral sclerosis. Mitochondrion. 2021;58:102&#x2013;110. doi: 10.1016/j.mito.2021.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mito.2021.02.008</ArticleId><ArticleId IdType="pubmed">33639271</ArticleId></ArticleIdList></Reference><Reference><Citation>Debska-Vielhaber G, et al. Impairment of mitochondrial oxidative phosphorylation in skin fibroblasts of SALS and FALS patients is rescued by in vitro treatment with ROS scavengers. Exp. Neurol. 2021;339:113620. doi: 10.1016/j.expneurol.2021.113620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2021.113620</ArticleId><ArticleId IdType="pubmed">33497646</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard-Marissal N, Chrast R, Schneider BL. Endoplasmic reticulum and mitochondria in diseases of motor and sensory neurons: a broken relationship? Cell Death Dis. 2018;9:333. doi: 10.1038/s41419-017-0125-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-017-0125-1</ArticleId><ArticleId IdType="pmc">PMC5832431</ArticleId><ArticleId IdType="pubmed">29491369</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankovic M, et al. Current concepts on genetic aspects of mitochondrial dysfunction in amyotrophic lateral sclerosis. Int. J. Mol. Sci. 2021;22:9832. doi: 10.3390/ijms22189832.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22189832</ArticleId><ArticleId IdType="pmc">PMC8469731</ArticleId><ArticleId IdType="pubmed">34575995</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SY, et al. C9ORF72-ALS/FTD-associated poly(GR) binds Atp5a1 and compromises mitochondrial function in vivo. Nat. Neurosci. 2019;22:851&#x2013;862. doi: 10.1038/s41593-019-0397-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0397-0</ArticleId><ArticleId IdType="pmc">PMC6800116</ArticleId><ArticleId IdType="pubmed">31086314</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang T, et al. C9orf72 regulates energy homeostasis by stabilizing mitochondrial complex I assembly. Cell Metab. 2021;33:531&#x2013;546.e9. doi: 10.1016/j.cmet.2021.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2021.01.005</ArticleId><ArticleId IdType="pmc">PMC8579819</ArticleId><ArticleId IdType="pubmed">33545050</ArticleId></ArticleIdList></Reference><Reference><Citation>Izumikawa K, et al. TDP-43 stabilises the processing intermediates of mitochondrial transcripts. Sci. Rep. 2017;7:7709. doi: 10.1038/s41598-017-06953-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-06953-y</ArticleId><ArticleId IdType="pmc">PMC5550480</ArticleId><ArticleId IdType="pubmed">28794432</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol. 2013;12:1059&#x2013;1067. doi: 10.1016/S1474-4422(13)70221-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70221-7</ArticleId><ArticleId IdType="pubmed">24067398</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastula DM, Moore DH, Bedlack RS. Creatine for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst. Rev. 2012;12:CD005225.</Citation><ArticleIdList><ArticleId IdType="pubmed">23235621</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann P, et al. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann. Neurol. 2009;66:235&#x2013;244. doi: 10.1002/ana.21743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21743</ArticleId><ArticleId IdType="pmc">PMC2854625</ArticleId><ArticleId IdType="pubmed">19743457</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenglet T, et al. A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis. Eur. J. Neurol. 2014;21:529&#x2013;536. doi: 10.1111/ene.12344.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12344</ArticleId><ArticleId IdType="pubmed">24447620</ArticleId></ArticleIdList></Reference><Reference><Citation>Elia AE, et al. Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. Eur. J. Neurol. 2016;23:45&#x2013;52. doi: 10.1111/ene.12664.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.12664</ArticleId><ArticleId IdType="pmc">PMC5024041</ArticleId><ArticleId IdType="pubmed">25664595</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, et al. Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis. Muscle Nerve. 2021;63:31&#x2013;39. doi: 10.1002/mus.27091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27091</ArticleId><ArticleId IdType="pmc">PMC7820979</ArticleId><ArticleId IdType="pubmed">33063909</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, et al. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N. Engl. J. Med. 2020;383:919&#x2013;930. doi: 10.1056/NEJMoa1916945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1916945</ArticleId><ArticleId IdType="pmc">PMC9134321</ArticleId><ArticleId IdType="pubmed">32877582</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi SY, et al. Prevention of mitochondrial impairment by inhibition of protein phosphatase 1 activity in amyotrophic lateral sclerosis. Cell Death Dis. 2020;11:888. doi: 10.1038/s41419-020-03102-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-020-03102-8</ArticleId><ArticleId IdType="pmc">PMC7578657</ArticleId><ArticleId IdType="pubmed">33087694</ArticleId></ArticleIdList></Reference><Reference><Citation>Sassani M, et al. Magnetic resonance spectroscopy reveals mitochondrial dysfunction in amyotrophic lateral sclerosis. Brain. 2020;143:3603&#x2013;3618. doi: 10.1093/brain/awaa340.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awaa340</ArticleId><ArticleId IdType="pubmed">33439988</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster CP, Smith EF, Shaw PJ, De Vos KJ. Protein homeostasis in amyotrophic lateral sclerosis: therapeutic opportunities? Front. Mol. Neurosci. 2017;10:123. doi: 10.3389/fnmol.2017.00123.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00123</ArticleId><ArticleId IdType="pmc">PMC5411428</ArticleId><ArticleId IdType="pubmed">28512398</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramesh N, Pandey UB. Autophagy dysregulation in ALS: when protein aggregates get out of hand. Front. Mol. Neurosci. 2017;10:263. doi: 10.3389/fnmol.2017.00263.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00263</ArticleId><ArticleId IdType="pmc">PMC5572252</ArticleId><ArticleId IdType="pubmed">28878620</ArticleId></ArticleIdList></Reference><Reference><Citation>Montibeller L, Tan LY, Kim JK, Paul P, de Belleroche J. Tissue-selective regulation of protein homeostasis and unfolded protein response signalling in sporadic ALS. J. Cell Mol. Med. 2020;24:6055&#x2013;6069. doi: 10.1111/jcmm.15170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.15170</ArticleId><ArticleId IdType="pmc">PMC7294118</ArticleId><ArticleId IdType="pubmed">32324341</ArticleId></ArticleIdList></Reference><Reference><Citation>Oakes JA, Davies MC, Collins MO. TBK1: a new player in ALS linking autophagy and neuroinflammation. Mol. Brain. 2017;10:5. doi: 10.1186/s13041-017-0287-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13041-017-0287-x</ArticleId><ArticleId IdType="pmc">PMC5288885</ArticleId><ArticleId IdType="pubmed">28148298</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster CP, et al. The C9orf72 protein interacts with Rab1a and the ULK1 complex to regulate initiation of autophagy. EMBO J. 2016;35:1656&#x2013;1676. doi: 10.15252/embj.201694401.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.201694401</ArticleId><ArticleId IdType="pmc">PMC4969571</ArticleId><ArticleId IdType="pubmed">27334615</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster AD, Rea SL. The role of sequestosome 1/p62 protein in amyotrophic lateral sclerosis and frontotemporal dementia pathogenesis. Neural Regen. Res. 2020;15:2186&#x2013;2194. doi: 10.4103/1673-5374.284977.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.284977</ArticleId><ArticleId IdType="pmc">PMC7749485</ArticleId><ArticleId IdType="pubmed">32594029</ArticleId></ArticleIdList></Reference><Reference><Citation>Ying H, Yue BY. Optineurin: the autophagy connection. Exp. Eye Res. 2016;144:73&#x2013;80. doi: 10.1016/j.exer.2015.06.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exer.2015.06.029</ArticleId><ArticleId IdType="pmc">PMC4698099</ArticleId><ArticleId IdType="pubmed">26142952</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothenberg C, et al. Ubiquilin functions in autophagy and is degraded by chaperone-mediated autophagy. Hum. Mol. Genet. 2010;19:3219&#x2013;3232. doi: 10.1093/hmg/ddq231.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddq231</ArticleId><ArticleId IdType="pmc">PMC2908472</ArticleId><ArticleId IdType="pubmed">20529957</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu JJ, et al. ALS/FTD mutations in UBQLN2 impede autophagy by reducing autophagosome acidification through loss of function. Proc. Natl Acad. Sci. USA. 2020;117:15230&#x2013;15241. doi: 10.1073/pnas.1917371117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1917371117</ArticleId><ArticleId IdType="pmc">PMC7334651</ArticleId><ArticleId IdType="pubmed">32513711</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen DKH, Thombre R, Wang J. Autophagy as a common pathway in amyotrophic lateral sclerosis. Neurosci. Lett. 2019;697:34&#x2013;48. doi: 10.1016/j.neulet.2018.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2018.04.006</ArticleId><ArticleId IdType="pmc">PMC6170747</ArticleId><ArticleId IdType="pubmed">29626651</ArticleId></ArticleIdList></Reference><Reference><Citation>Brockington A, et al. Unravelling the enigma of selective vulnerability in neurodegeneration: motor neurons resistant to degeneration in ALS show distinct gene expression characteristics and decreased susceptibility to excitotoxicity. Acta Neuropathol. 2013;125:95&#x2013;109. doi: 10.1007/s00401-012-1058-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-012-1058-5</ArticleId><ArticleId IdType="pmc">PMC3535376</ArticleId><ArticleId IdType="pubmed">23143228</ArticleId></ArticleIdList></Reference><Reference><Citation>Yerbury JJ, Farrawell NE, McAlary L. Proteome homeostasis dysfunction: a unifying principle in ALS pathogenesis. Trends Neurosci. 2020;43:274&#x2013;284. doi: 10.1016/j.tins.2020.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2020.03.002</ArticleId><ArticleId IdType="pubmed">32353332</ArticleId></ArticleIdList></Reference><Reference><Citation>Suk TR, Rousseaux MWC. The role of TDP-43 mislocalization in amyotrophic lateral sclerosis. Mol. Neurodegener. 2020;15:45. doi: 10.1186/s13024-020-00397-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-00397-1</ArticleId><ArticleId IdType="pmc">PMC7429473</ArticleId><ArticleId IdType="pubmed">32799899</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitra J, et al. Motor neuron disease-associated loss of nuclear TDP-43 is linked to DNA double-strand break repair defects. Proc. Natl Acad. Sci. USA. 2019;116:4696&#x2013;4705. doi: 10.1073/pnas.1818415116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1818415116</ArticleId><ArticleId IdType="pmc">PMC6410842</ArticleId><ArticleId IdType="pubmed">30770445</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagano S, et al. TDP-43 transports ribosomal protein mRNA to regulate axonal local translation in neuronal axons. Acta Neuropathol. 2020;140:695&#x2013;713. doi: 10.1007/s00401-020-02205-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02205-y</ArticleId><ArticleId IdType="pubmed">32803350</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown AL. e. a. TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A. Nature. 2022;603:131&#x2013;137. doi: 10.1038/s41586-022-04436-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04436-3</ArticleId><ArticleId IdType="pmc">PMC8891020</ArticleId><ArticleId IdType="pubmed">35197628</ArticleId></ArticleIdList></Reference><Reference><Citation>Dyer MS, et al. Mislocalisation of TDP-43 to the cytoplasm causes cortical hyperexcitability and reduced excitatory neurotransmission in the motor cortex. J. Neurochem. 2021;157:1300&#x2013;1315. doi: 10.1111/jnc.15214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.15214</ArticleId><ArticleId IdType="pubmed">33064315</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeynaems S, et al. Phase separation of C9orf72 dipeptide repeats perturbs stress granule dynamics. Mol. Cell. 2017;65:1044&#x2013;1055.e5. doi: 10.1016/j.molcel.2017.02.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2017.02.013</ArticleId><ArticleId IdType="pmc">PMC5364369</ArticleId><ArticleId IdType="pubmed">28306503</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratti A, et al. Chronic stress induces formation of stress granules and pathological TDP-43 aggregates in human ALS fibroblasts and iPSC-motoneurons. Neurobiol. Dis. 2020;145:105051. doi: 10.1016/j.nbd.2020.105051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2020.105051</ArticleId><ArticleId IdType="pubmed">32827688</ArticleId></ArticleIdList></Reference><Reference><Citation>Baradaran-Heravi Y, Van Broeckhoven C, van der Zee J. Stress granule mediated protein aggregation and underlying gene defects in the FTD-ALS spectrum. Neurobiol. Dis. 2020;134:104639. doi: 10.1016/j.nbd.2019.104639.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2019.104639</ArticleId><ArticleId IdType="pubmed">31626953</ArticleId></ArticleIdList></Reference><Reference><Citation>Nahm M, et al. ANXA11 mutations in ALS cause dysregulation of calcium homeostasis and stress granule dynamics. Sci. Transl. Med. 2020;12:eaax3993. doi: 10.1126/scitranslmed.aax3993.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aax3993</ArticleId><ArticleId IdType="pubmed">33087501</ArticleId></ArticleIdList></Reference><Reference><Citation>Gwon Y, et al. Ubiquitination of G3BP1 mediates stress granule disassembly in a context-specific manner. Science. 2021;372:eabf6548. doi: 10.1126/science.abf6548.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf6548</ArticleId><ArticleId IdType="pmc">PMC8574224</ArticleId><ArticleId IdType="pubmed">34739333</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E. Targeting TDP-43 proteinopathy with drugs and drug-like small molecules. Br. J. Pharmacol. 2021;178:1298&#x2013;1315. doi: 10.1111/bph.15148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.15148</ArticleId><ArticleId IdType="pubmed">32469420</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalmar B, Greensmith L. Cellular chaperones as therapeutic targets in ALS to restore protein homeostasis and improve cellular function. Front. Mol. Neurosci. 2017;10:251. doi: 10.3389/fnmol.2017.00251.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00251</ArticleId><ArticleId IdType="pmc">PMC5596081</ArticleId><ArticleId IdType="pubmed">28943839</ArticleId></ArticleIdList></Reference><Reference><Citation>GlobalData Healthcare. Orphazyme&#x2019;s arimoclomol fails to show efficacy in a specific ALS population. Clinical Trials Arenahttps://www.clinicaltrialsarena.com/comment/orphazyme-arimoclomol-als/ (2021).</Citation></Reference><Reference><Citation>Wang IF, Tsai KJ, Shen CK. Autophagy activation ameliorates neuronal pathogenesis of FTLD-U mice: a new light for treatment of TARDBP/TDP-43 proteinopathies. Autophagy. 2013;9:239&#x2013;240. doi: 10.4161/auto.22526.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/auto.22526</ArticleId><ArticleId IdType="pmc">PMC3552888</ArticleId><ArticleId IdType="pubmed">23108236</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, et al. Trehalose decreases mutant SOD1 expression and alleviates motor deficiency in early but not end-stage amyotrophic lateral sclerosis in a SOD1-G93A mouse model. Neuroscience. 2015;298:12&#x2013;25. doi: 10.1016/j.neuroscience.2015.03.061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2015.03.061</ArticleId><ArticleId IdType="pubmed">25841320</ArticleId></ArticleIdList></Reference><Reference><Citation>Barmada SJ, et al. Autophagy induction enhances TDP43 turnover and survival in neuronal ALS models. Nat. Chem. Biol. 2014;10:677&#x2013;685. doi: 10.1038/nchembio.1563.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nchembio.1563</ArticleId><ArticleId IdType="pmc">PMC4106236</ArticleId><ArticleId IdType="pubmed">24974230</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang MY, et al. Small-molecule modulation of TDP-43 recruitment to stress granules prevents persistent TDP-43 accumulation in ALS/FTD. Neuron. 2019;103:802&#x2013;819.e11. doi: 10.1016/j.neuron.2019.05.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.05.048</ArticleId><ArticleId IdType="pmc">PMC6728177</ArticleId><ArticleId IdType="pubmed">31272829</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubinski A, Vande Velde C. Altered stress granule disassembly: links to neurodegenerative disease? Trends Neurosci. 2021;44:765&#x2013;766. doi: 10.1016/j.tins.2021.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2021.08.001</ArticleId><ArticleId IdType="pubmed">34429216</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel SH, Beers DR, Zhao W. Amyotrophic lateral sclerosis is a systemic disease: peripheral contributions to inflammation-mediated neurodegeneration. Curr. Opin. Neurol. 2021;34:765&#x2013;772. doi: 10.1097/WCO.0000000000000983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000983</ArticleId><ArticleId IdType="pubmed">34402459</ArticleId></ArticleIdList></Reference><Reference><Citation>Vu L, et al. Cross-sectional and longitudinal measures of chitinase proteins in amyotrophic lateral sclerosis and expression of CHI3L1 in activated astrocytes. J. Neurol. Neurosurg. Psychiatry. 2020;91:350&#x2013;358. doi: 10.1136/jnnp-2019-321916.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-321916</ArticleId><ArticleId IdType="pmc">PMC7147184</ArticleId><ArticleId IdType="pubmed">31937582</ArticleId></ArticleIdList></Reference><Reference><Citation>Westergard T, Rothstein JD. Astrocyte diversity: current insights and future directions. Neurochem. Res. 2020;45:1298&#x2013;1305. doi: 10.1007/s11064-020-02959-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-020-02959-7</ArticleId><ArticleId IdType="pmc">PMC8715392</ArticleId><ArticleId IdType="pubmed">32006215</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka K, Komine O. The multi-dimensional roles of astrocytes in ALS. Neurosci. Res. 2018;126:31&#x2013;38. doi: 10.1016/j.neures.2017.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neures.2017.09.011</ArticleId><ArticleId IdType="pubmed">29054467</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer K, et al. Direct conversion of patient fibroblasts demonstrates non-cell autonomous toxicity of astrocytes to motor neurons in familial and sporadic ALS. Proc. Natl Acad. Sci. USA. 2014;111:829&#x2013;832. doi: 10.1073/pnas.1314085111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1314085111</ArticleId><ArticleId IdType="pmc">PMC3896192</ArticleId><ArticleId IdType="pubmed">24379375</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraiuolo L, et al. Dysregulation of astrocyte-motoneuron cross-talk in mutant superoxide dismutase 1-related amyotrophic lateral sclerosis. Brain. 2011;134:2627&#x2013;2641. doi: 10.1093/brain/awr193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr193</ArticleId><ArticleId IdType="pmc">PMC3170534</ArticleId><ArticleId IdType="pubmed">21908873</ArticleId></ArticleIdList></Reference><Reference><Citation>Butovsky O, Weiner HL. Microglial signatures and their role in health and disease. Nat. Rev. Neurosci. 2018;19:622&#x2013;635. doi: 10.1038/s41583-018-0057-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41583-018-0057-5</ArticleId><ArticleId IdType="pmc">PMC7255106</ArticleId><ArticleId IdType="pubmed">30206328</ArticleId></ArticleIdList></Reference><Reference><Citation>Cassina P, Miquel E, Martinez-Palma L, Cassina A. Glial metabolic reprogramming in amyotrophic lateral sclerosis. Neuroimmunomodulation. 2021;28:204&#x2013;212. doi: 10.1159/000516926.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000516926</ArticleId><ArticleId IdType="pubmed">34175843</ArticleId></ArticleIdList></Reference><Reference><Citation>Haukedal H, Freude K. Implications of microglia in amyotrophic lateral sclerosis and frontotemporal dementia. J. Mol. Biol. 2019;431:1818&#x2013;1829. doi: 10.1016/j.jmb.2019.02.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2019.02.004</ArticleId><ArticleId IdType="pubmed">30763568</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao B, Zhao W, Beers DR, Henkel JS, Appel SH. Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS. Exp. Neurol. 2012;237:147&#x2013;152. doi: 10.1016/j.expneurol.2012.06.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2012.06.011</ArticleId><ArticleId IdType="pmc">PMC4126417</ArticleId><ArticleId IdType="pubmed">22735487</ArticleId></ArticleIdList></Reference><Reference><Citation>Du Y, et al. Increased activation ability of monocytes from ALS patients. Exp. Neurol. 2020;328:113259. doi: 10.1016/j.expneurol.2020.113259.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2020.113259</ArticleId><ArticleId IdType="pubmed">32105709</ArticleId></ArticleIdList></Reference><Reference><Citation>Haidet-Phillips AM, et al. Astrocytes from familial and sporadic ALS patients are toxic to motor neurons. Nat. Biotechnol. 2011;29:824&#x2013;828. doi: 10.1038/nbt.1957.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.1957</ArticleId><ArticleId IdType="pmc">PMC3170425</ArticleId><ArticleId IdType="pubmed">21832997</ArticleId></ArticleIdList></Reference><Reference><Citation>Frakes AE, et al. Microglia induce motor neuron death via the classical NF-&#x3ba;B pathway in amyotrophic lateral sclerosis. Neuron. 2014;81:1009&#x2013;1023. doi: 10.1016/j.neuron.2014.01.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.01.013</ArticleId><ArticleId IdType="pmc">PMC3978641</ArticleId><ArticleId IdType="pubmed">24607225</ArticleId></ArticleIdList></Reference><Reference><Citation>Smethurst P, et al. Distinct responses of neurons and astrocytes to TDP-43 proteinopathy in amyotrophic lateral sclerosis. Brain. 2020;143:430&#x2013;440. doi: 10.1093/brain/awz419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz419</ArticleId><ArticleId IdType="pmc">PMC7009461</ArticleId><ArticleId IdType="pubmed">32040555</ArticleId></ArticleIdList></Reference><Reference><Citation>Svahn AJ, et al. Nucleo-cytoplasmic transport of TDP-43 studied in real time: impaired microglia function leads to axonal spreading of TDP-43 in degenerating motor neurons. Acta Neuropathol. 2018;136:445&#x2013;459. doi: 10.1007/s00401-018-1875-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1875-2</ArticleId><ArticleId IdType="pmc">PMC6096729</ArticleId><ArticleId IdType="pubmed">29943193</ArticleId></ArticleIdList></Reference><Reference><Citation>Jara JH, et al. MCP1-CCR2 and neuroinflammation in the ALS motor cortex with TDP-43 pathology. J. Neuroinflammation. 2019;16:196. doi: 10.1186/s12974-019-1589-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-019-1589-y</ArticleId><ArticleId IdType="pmc">PMC6822373</ArticleId><ArticleId IdType="pubmed">31666087</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu CH, et al. TDP-43 triggers mitochondrial DNA release via mPTP to activate cGAS/STING in ALS. Cell. 2020;183:636&#x2013;649.e18. doi: 10.1016/j.cell.2020.09.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.020</ArticleId><ArticleId IdType="pmc">PMC7599077</ArticleId><ArticleId IdType="pubmed">33031745</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JD, Woodruff TM. TDP-43 puts the STING in ALS. Trends Neurosci. 2021;44:81&#x2013;82. doi: 10.1016/j.tins.2020.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2020.12.001</ArticleId><ArticleId IdType="pubmed">33353765</ArticleId></ArticleIdList></Reference><Reference><Citation>Morello G, Spampinato AG, Cavallaro S. Neuroinflammation and ALS: transcriptomic insights into molecular disease mechanisms and therapeutic targets. Mediators Inflamm. 2017;2017:7070469. doi: 10.1155/2017/7070469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/7070469</ArticleId><ArticleId IdType="pmc">PMC5610842</ArticleId><ArticleId IdType="pubmed">29081603</ArticleId></ArticleIdList></Reference><Reference><Citation>Pang W, Hu F. Cellular and physiological functions of C9ORF72 and implications for ALS/FTD. J. Neurochem. 2021;157:334&#x2013;350. doi: 10.1111/jnc.15255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.15255</ArticleId><ArticleId IdType="pmc">PMC8842544</ArticleId><ArticleId IdType="pubmed">33259633</ArticleId></ArticleIdList></Reference><Reference><Citation>McCauley ME, et al. C9orf72 in myeloid cells suppresses STING-induced inflammation. Nature. 2020;585:96&#x2013;101. doi: 10.1038/s41586-020-2625-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2625-x</ArticleId><ArticleId IdType="pmc">PMC7484469</ArticleId><ArticleId IdType="pubmed">32814898</ArticleId></ArticleIdList></Reference><Reference><Citation>Werry EL, et al. Recent developments in TSPO PET imaging as a biomarker of neuroinflammation in neurodegenerative disorders. Int. J. Mol. Sci. 2019;20:3161. doi: 10.3390/ijms20133161.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20133161</ArticleId><ArticleId IdType="pmc">PMC6650818</ArticleId><ArticleId IdType="pubmed">31261683</ArticleId></ArticleIdList></Reference><Reference><Citation>Kok JR, Palminha NM, Dos Santos Souza C, El-Khamisy SF, Ferraiuolo L. DNA damage as a mechanism of neurodegeneration in ALS and a contributor to astrocyte toxicity. Cell Mol. Life Sci. 2021;78:5707&#x2013;5729. doi: 10.1007/s00018-021-03872-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-021-03872-0</ArticleId><ArticleId IdType="pmc">PMC8316199</ArticleId><ArticleId IdType="pubmed">34173837</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrante RJ, et al. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J. Neurochem. 1997;69:2064&#x2013;2074. doi: 10.1046/j.1471-4159.1997.69052064.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1997.69052064.x</ArticleId><ArticleId IdType="pubmed">9349552</ArticleId></ArticleIdList></Reference><Reference><Citation>Bogdanov M, et al. Increased oxidative damage to DNA in ALS patients. Free. Radic. Biol. Med. 2000;29:652&#x2013;658. doi: 10.1016/S0891-5849(00)00349-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0891-5849(00)00349-X</ArticleId><ArticleId IdType="pubmed">11033417</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim BW, Jeong YE, Wong M, Martin LJ. DNA damage accumulates and responses are engaged in human ALS brain and spinal motor neurons and DNA repair is activatable in iPSC-derived motor neurons with SOD1 mutations. Acta Neuropathol. Commun. 2020;8:7. doi: 10.1186/s40478-019-0874-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-019-0874-4</ArticleId><ArticleId IdType="pmc">PMC6995159</ArticleId><ArticleId IdType="pubmed">32005289</ArticleId></ArticleIdList></Reference><Reference><Citation>Farg MA, Konopka A, Soo KY, Ito D, Atkin JD. The DNA damage response (DDR) is induced by the C9orf72 repeat expansion in amyotrophic lateral sclerosis. Hum. Mol. Genet. 2017;26:2882&#x2013;2896. doi: 10.1093/hmg/ddx170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddx170</ArticleId><ArticleId IdType="pubmed">28481984</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Gonzalez R, et al. Poly(GR) in C9ORF72-related ALS/FTD compromises mitochondrial function and increases oxidative stress and DNA damage in iPSC-derived motor neurons. Neuron. 2016;92:383&#x2013;391. doi: 10.1016/j.neuron.2016.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.09.015</ArticleId><ArticleId IdType="pmc">PMC5111366</ArticleId><ArticleId IdType="pubmed">27720481</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker C, et al. C9orf72 expansion disrupts ATM-mediated chromosomal break repair. Nat. Neurosci. 2017;20:1225&#x2013;1235. doi: 10.1038/nn.4604.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4604</ArticleId><ArticleId IdType="pmc">PMC5578434</ArticleId><ArticleId IdType="pubmed">28714954</ArticleId></ArticleIdList></Reference><Reference><Citation>Konopka A, et al. Impaired NHEJ repair in amyotrophic lateral sclerosis is associated with TDP-43 mutations. Mol. Neurodegener. 2020;15:51. doi: 10.1186/s13024-020-00386-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-00386-4</ArticleId><ArticleId IdType="pmc">PMC7488163</ArticleId><ArticleId IdType="pubmed">32907630</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannini M, et al. TDP-43 mutations link amyotrophic lateral sclerosis with R-loop homeostasis and R loop-mediated DNA damage. PLoS Genet. 2020;16:e1009260. doi: 10.1371/journal.pgen.1009260.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1009260</ArticleId><ArticleId IdType="pmc">PMC7755276</ArticleId><ArticleId IdType="pubmed">33301444</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, et al. Mutant FUS causes DNA ligation defects to inhibit oxidative damage repair in amyotrophic lateral sclerosis. Nat. Commun. 2018;9:3683. doi: 10.1038/s41467-018-06111-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-06111-6</ArticleId><ArticleId IdType="pmc">PMC6134028</ArticleId><ArticleId IdType="pubmed">30206235</ArticleId></ArticleIdList></Reference><Reference><Citation>Higelin J, et al. NEK1 loss-of-function mutation induces DNA damage accumulation in ALS patient-derived motoneurons. Stem Cell Res. 2018;30:150&#x2013;162. doi: 10.1016/j.scr.2018.06.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.scr.2018.06.005</ArticleId><ArticleId IdType="pubmed">29929116</ArticleId></ArticleIdList></Reference><Reference><Citation>Butti Z, Patten SA. RNA dysregulation in amyotrophic lateral sclerosis. Front. Genet. 2018;9:712. doi: 10.3389/fgene.2018.00712.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2018.00712</ArticleId><ArticleId IdType="pmc">PMC6349704</ArticleId><ArticleId IdType="pubmed">30723494</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C, et al. Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 intersect in processing long pre-mRNAs. Nat. Neurosci. 2012;15:1488&#x2013;1497. doi: 10.1038/nn.3230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3230</ArticleId><ArticleId IdType="pmc">PMC3586380</ArticleId><ArticleId IdType="pubmed">23023293</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YB, et al. Hexanucleotide repeats in ALS/FTD form length-dependent RNA foci, sequester RNA binding proteins, and are neurotoxic. Cell Rep. 2013;5:1178&#x2013;1186. doi: 10.1016/j.celrep.2013.10.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2013.10.049</ArticleId><ArticleId IdType="pmc">PMC3898469</ArticleId><ArticleId IdType="pubmed">24290757</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J, et al. Sequestration of multiple RNA recognition motif-containing proteins by C9orf72 repeat expansions. Brain. 2014;137:2040&#x2013;2051. doi: 10.1093/brain/awu120.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awu120</ArticleId><ArticleId IdType="pmc">PMC4065024</ArticleId><ArticleId IdType="pubmed">24866055</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly CJ, et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron. 2013;80:415&#x2013;428. doi: 10.1016/j.neuron.2013.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.10.015</ArticleId><ArticleId IdType="pmc">PMC4098943</ArticleId><ArticleId IdType="pubmed">24139042</ArticleId></ArticleIdList></Reference><Reference><Citation>Lagier-Tourenne C, et al. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc. Natl Acad. Sci. USA. 2013;110:E4530&#x2013;E4539. doi: 10.1073/pnas.1318835110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1318835110</ArticleId><ArticleId IdType="pmc">PMC3839752</ArticleId><ArticleId IdType="pubmed">24170860</ArticleId></ArticleIdList></Reference><Reference><Citation>Hautbergue GM, et al. SRSF1-dependent nuclear export inhibition of C9ORF72 repeat transcripts prevents neurodegeneration and associated motor deficits. Nat. Commun. 2017;8:16063. doi: 10.1038/ncomms16063.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms16063</ArticleId><ArticleId IdType="pmc">PMC5504286</ArticleId><ArticleId IdType="pubmed">28677678</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeynaems S, et al. Drosophila screen connects nuclear transport genes to DPR pathology in c9ALS/FTD. Sci. Rep. 2016;6:20877. doi: 10.1038/srep20877.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep20877</ArticleId><ArticleId IdType="pmc">PMC4751451</ArticleId><ArticleId IdType="pubmed">26869068</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum BD, et al. GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. Nature. 2015;525:129&#x2013;133. doi: 10.1038/nature14974.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14974</ArticleId><ArticleId IdType="pmc">PMC4631399</ArticleId><ArticleId IdType="pubmed">26308899</ArticleId></ArticleIdList></Reference><Reference><Citation>Jovicic A, et al. Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS. Nat. Neurosci. 2015;18:1226&#x2013;1229. doi: 10.1038/nn.4085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4085</ArticleId><ArticleId IdType="pmc">PMC4552077</ArticleId><ArticleId IdType="pubmed">26308983</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, et al. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature. 2015;525:56&#x2013;61. doi: 10.1038/nature14973.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14973</ArticleId><ArticleId IdType="pmc">PMC4800742</ArticleId><ArticleId IdType="pubmed">26308891</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, et al. Stress granule assembly disrupts nucleocytoplasmic transport. Cell. 2018;173:958&#x2013;971.e17. doi: 10.1016/j.cell.2018.03.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.03.025</ArticleId><ArticleId IdType="pmc">PMC6083872</ArticleId><ArticleId IdType="pubmed">29628143</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand AA, Walter P. Structural insights into ISRIB, a memory-enhancing inhibitor of the integrated stress response. FEBS J. 2020;287:239&#x2013;245. doi: 10.1111/febs.15073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/febs.15073</ArticleId><ArticleId IdType="pubmed">31550413</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou CC, et al. TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD. Nat. Neurosci. 2018;21:228&#x2013;239. doi: 10.1038/s41593-017-0047-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-017-0047-3</ArticleId><ArticleId IdType="pmc">PMC5800968</ArticleId><ArticleId IdType="pubmed">29311743</ArticleId></ArticleIdList></Reference><Reference><Citation>Ederle H, et al. Nuclear egress of TDP-43 and FUS occurs independently of exportin-1/CRM1. Sci. Rep. 2018;8:7084. doi: 10.1038/s41598-018-25007-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-25007-5</ArticleId><ArticleId IdType="pmc">PMC5935713</ArticleId><ArticleId IdType="pubmed">29728564</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J, et al. LSM12-EPAC1 defines a neuroprotective pathway that sustains the nucleocytoplasmic RAN gradient. PLoS Biol. 2020;18:e3001002. doi: 10.1371/journal.pbio.3001002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.3001002</ArticleId><ArticleId IdType="pmc">PMC7757817</ArticleId><ArticleId IdType="pubmed">33362237</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vos KJ, Grierson AJ, Ackerley S, Miller CC. Role of axonal transport in neurodegenerative diseases. Annu. Rev. Neurosci. 2008;31:151&#x2013;173. doi: 10.1146/annurev.neuro.31.061307.090711.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.31.061307.090711</ArticleId><ArticleId IdType="pubmed">18558852</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolas A, et al. Genome-wide analyses identify KIF5A as a novel ALS gene. Neuron. 2018;97:1268&#x2013;1283.e6. doi: 10.1016/j.neuron.2018.02.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2018.02.027</ArticleId><ArticleId IdType="pmc">PMC5867896</ArticleId><ArticleId IdType="pubmed">29566793</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao YC, et al. RNA granules hitchhike on lysosomes for long-distance transport, using annexin A11 as a molecular tether. Cell. 2019;179:147&#x2013;164.e20. doi: 10.1016/j.cell.2019.08.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.08.050</ArticleId><ArticleId IdType="pmc">PMC6890474</ArticleId><ArticleId IdType="pubmed">31539493</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbs KL, et al. Inhibiting p38 MAPK alpha rescues axonal retrograde transport defects in a mouse model of ALS. Cell Death Dis. 2018;9:596. doi: 10.1038/s41419-018-0624-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-018-0624-8</ArticleId><ArticleId IdType="pmc">PMC5964181</ArticleId><ArticleId IdType="pubmed">29789529</ArticleId></ArticleIdList></Reference><Reference><Citation>Fellows AD, Rhymes ER, Gibbs KL, Greensmith L, Schiavo G. IGF1R regulates retrograde axonal transport of signalling endosomes in motor neurons. EMBO Rep. 2020;21:e49129. doi: 10.15252/embr.201949129.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embr.201949129</ArticleId><ArticleId IdType="pmc">PMC7054680</ArticleId><ArticleId IdType="pubmed">32030864</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W, et al. HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients. Nat. Commun. 2017;8:861. doi: 10.1038/s41467-017-00911-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00911-y</ArticleId><ArticleId IdType="pmc">PMC5636840</ArticleId><ArticleId IdType="pubmed">29021520</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleigh JN, et al. Mice carrying ALS mutant TDP-43, but not mutant FUS, display in vivo defects in axonal transport of signaling endosomes. Cell Rep. 2020;30:3655&#x2013;3662.e2. doi: 10.1016/j.celrep.2020.02.078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.02.078</ArticleId><ArticleId IdType="pmc">PMC7090381</ArticleId><ArticleId IdType="pubmed">32187538</ArticleId></ArticleIdList></Reference><Reference><Citation>Coleman MP, Hoke A. Programmed axon degeneration: from mouse to mechanism to medicine. Nat. Rev. Neurosci. 2020;21:183&#x2013;196. doi: 10.1038/s41583-020-0269-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41583-020-0269-3</ArticleId><ArticleId IdType="pmc">PMC8926152</ArticleId><ArticleId IdType="pubmed">32152523</ArticleId></ArticleIdList></Reference><Reference><Citation>White MA, et al. Sarm1 deletion suppresses TDP-43-linked motor neuron degeneration and cortical spine loss. Acta Neuropathol. Commun. 2019;7:166. doi: 10.1186/s40478-019-0800-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-019-0800-9</ArticleId><ArticleId IdType="pmc">PMC6819591</ArticleId><ArticleId IdType="pubmed">31661035</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker LA, et al. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice. Nature. 2017;544:367&#x2013;371. doi: 10.1038/nature22038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature22038</ArticleId><ArticleId IdType="pmc">PMC5642042</ArticleId><ArticleId IdType="pubmed">28405022</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray, F. Ionis Opening Phase 3 Trial of ION363, Antisense Therapy for FUS-ALS. ALShttps://alsnewstoday.com/news/ionis-opening-phase-3-trial-ion363-antisense-therapy-for-fus-als/ (2021).</Citation></Reference><Reference><Citation>Cudkowicz ME, et al. A randomized placebo-controlled phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis. Muscle Nerve. 2022;65:291&#x2013;302. doi: 10.1002/mus.27472.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27472</ArticleId><ArticleId IdType="pmc">PMC9305113</ArticleId><ArticleId IdType="pubmed">34890069</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, et al. A phase 2, double-blind, randomized, dose-ranging trial of reldesemtiv in patients with ALS. Amyotroph. Lateral Scler. Frontotemporal Degener. 2021;22:287&#x2013;299. doi: 10.1080/21678421.2020.1822410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1822410</ArticleId><ArticleId IdType="pmc">PMC8117790</ArticleId><ArticleId IdType="pubmed">32969758</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry JD, et al. NurOwn, phase 2, randomized, clinical trial in patients with ALS: safety, clinical, and biomarker results. Neurology. 2019;93:e2294&#x2013;e2305. doi: 10.1212/WNL.0000000000008620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000008620</ArticleId><ArticleId IdType="pmc">PMC6937497</ArticleId><ArticleId IdType="pubmed">31740545</ArticleId></ArticleIdList></Reference><Reference><Citation>Gothelf Y, Abramov N, Harel A, Offen D. Safety of repeated transplantations of neurotrophic factors-secreting human mesenchymal stromal stem cells. Clin. Transl. Med. 2014;3:21. doi: 10.1186/2001-1326-3-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2001-1326-3-21</ArticleId><ArticleId IdType="pmc">PMC4108239</ArticleId><ArticleId IdType="pubmed">25097724</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrou P, et al. Safety and clinical effects of mesenchymal stem cells secreting neurotrophic factor transplantation in patients with amyotrophic lateral sclerosis: results of phase 1/2 and 2a clinical trials. JAMA Neurol. 2016;73:337&#x2013;344. doi: 10.1001/jamaneurol.2015.4321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2015.4321</ArticleId><ArticleId IdType="pubmed">26751635</ArticleId></ArticleIdList></Reference><Reference><Citation>McCampbell A, et al. Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. J. Clin. Invest. 2018;128:3558&#x2013;3567. doi: 10.1172/JCI99081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI99081</ArticleId><ArticleId IdType="pmc">PMC6063493</ArticleId><ArticleId IdType="pubmed">30010620</ArticleId></ArticleIdList></Reference><Reference><Citation>Iannitti T, et al. Translating SOD1 gene silencing toward the clinic: a highly efficacious, off-target-free, and biomarker-supported strategy for fALS. Mol. Ther. Nucleic Acids. 2018;12:75&#x2013;88. doi: 10.1016/j.omtn.2018.04.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2018.04.015</ArticleId><ArticleId IdType="pmc">PMC6023790</ArticleId><ArticleId IdType="pubmed">30195799</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T, et al. Phase 1-2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N. Engl. J. Med. 2020;383:109&#x2013;119. doi: 10.1056/NEJMoa2003715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2003715</ArticleId><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller, T., Cudkowicz, M., on behalf of the VALOR Working Group. Results from the phase 3 VALOR study and its open-label extension: evaluating the clinical efficacy and safety of tofersen in adults with ALS and confirmed SOD1 mutation. Biogenhttps://biogen.gcs-web.com/static-files/b2154d4e-f69f-49d4-9a61-e834387293ea (2021).</Citation></Reference><Reference><Citation>Miller TM, et al. Trial of antisense oligonucleotide tofersen for SOD1 ALS. N. Engl. J. Med. 2022;387:1099&#x2013;1110. doi: 10.1056/NEJMoa2204705.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2204705</ArticleId><ArticleId IdType="pubmed">36129998</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonobe Y, et al. Translation of dipeptide repeat proteins from the C9ORF72 expanded repeat is associated with cellular stress. Neurobiol. Dis. 2018;116:155&#x2013;165. doi: 10.1016/j.nbd.2018.05.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2018.05.009</ArticleId><ArticleId IdType="pmc">PMC6331062</ArticleId><ArticleId IdType="pubmed">29792928</ArticleId></ArticleIdList></Reference><Reference><Citation>Van den Berg, L. H., et al. Results from the phase 1 trial and open-label extension evaluating BIIB078 in adults with C9orf72-ALS. Presented at ENCALS Meeting (2022).</Citation></Reference><Reference><Citation>Suaud L, et al. 4-Phenylbutyrate stimulates Hsp70 expression through the Elp2 component of elongator and STAT-3 in cystic fibrosis epithelial cells. J. Biol. Chem. 2011;286:45083&#x2013;45092. doi: 10.1074/jbc.M111.293282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.293282</ArticleId><ArticleId IdType="pmc">PMC3247989</ArticleId><ArticleId IdType="pubmed">22069317</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues CM, Sola S, Sharpe JC, Moura JJ, Steer CJ. Tauroursodeoxycholic acid prevents Bax-induced membrane perturbation and cytochrome c release in isolated mitochondria. Biochemistry. 2003;42:3070&#x2013;3080. doi: 10.1021/bi026979d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi026979d</ArticleId><ArticleId IdType="pubmed">12627974</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullard A. Amylyx&#x2019;s ALS therapy secures FDA approval, as regulatory flexibility trumps underwhelming data. Nat. Rev. Drug Discov. 2022;21:786.</Citation><ArticleIdList><ArticleId IdType="pubmed">36216876</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA Briefing Document NDA# 216660 (Peripheral and Central Nervous System Drugs Advisory Committee, 2022); https://www.fda.gov/media/161378/download</Citation></Reference><Reference><Citation>Tang Q, et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity. 2008;28:687&#x2013;697. doi: 10.1016/j.immuni.2008.03.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2008.03.016</ArticleId><ArticleId IdType="pmc">PMC2394854</ArticleId><ArticleId IdType="pubmed">18468463</ArticleId></ArticleIdList></Reference><Reference><Citation>Camu W, et al. Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial. EBioMedicine. 2020;59:102844. doi: 10.1016/j.ebiom.2020.102844.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2020.102844</ArticleId><ArticleId IdType="pmc">PMC7502670</ArticleId><ArticleId IdType="pubmed">32651161</ArticleId></ArticleIdList></Reference><Reference><Citation>Giovannelli I, et al. Amyotrophic lateral sclerosis transcriptomics reveals immunological effects of low-dose interleukin-2. Brain Commun. 2021;3:fcab141. doi: 10.1093/braincomms/fcab141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcab141</ArticleId><ArticleId IdType="pmc">PMC8364666</ArticleId><ArticleId IdType="pubmed">34409288</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalakas MC, Alexopoulos H, Spaeth PJ. Complement in neurological disorders and emerging complement-targeted therapeutics. Nat. Rev. Neurol. 2020;16:601&#x2013;617. doi: 10.1038/s41582-020-0400-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-020-0400-0</ArticleId><ArticleId IdType="pmc">PMC7528717</ArticleId><ArticleId IdType="pubmed">33005040</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahia El Idrissi N, et al. Complement activation at the motor end-plates in amyotrophic lateral sclerosis. J. Neuroinflammation. 2016;13:72. doi: 10.1186/s12974-016-0538-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-016-0538-2</ArticleId><ArticleId IdType="pmc">PMC4823861</ArticleId><ArticleId IdType="pubmed">27056040</ArticleId></ArticleIdList></Reference><Reference><Citation>Wainger BJ, et al. Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. Cell Rep. 2014;7:1&#x2013;11. doi: 10.1016/j.celrep.2014.03.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2014.03.019</ArticleId><ArticleId IdType="pmc">PMC4023477</ArticleId><ArticleId IdType="pubmed">24703839</ArticleId></ArticleIdList></Reference><Reference><Citation>Wainger BJ, et al. Effect of ezogabine on cortical and spinal motor neuron excitability in amyotrophic lateral sclerosis: a randomized clinical trial. JAMA Neurol. 2021;78:186&#x2013;196. doi: 10.1001/jamaneurol.2020.4300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.4300</ArticleId><ArticleId IdType="pmc">PMC7684515</ArticleId><ArticleId IdType="pubmed">33226425</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell A, Baldessarini RJ, Teicher MH, Neumeyer JL. S(+)apomorphines. selective inhibition of excitatory effects of dopamine injected into the limbic system of the rat. Neuropharmacology. 1985;24:391&#x2013;399. doi: 10.1016/0028-3908(85)90023-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0028-3908(85)90023-1</ArticleId><ArticleId IdType="pubmed">4022264</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaus JM, Titus RD, Foreman MM, Mason NR, Truex LL. Aporphines as antagonists of dopamine D-1 receptors. J. Med. Chem. 1990;33:600&#x2013;607. doi: 10.1021/jm00164a022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm00164a022</ArticleId><ArticleId IdType="pubmed">2405158</ArticleId></ArticleIdList></Reference><Reference><Citation>Mead RJ, et al. S[+] Apomorphine is a CNS penetrating activator of the Nrf2-ARE pathway with activity in mouse and patient fibroblast models of amyotrophic lateral sclerosis. Free Radic. Biol. Med. 2013;61:438&#x2013;452. doi: 10.1016/j.freeradbiomed.2013.04.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2013.04.018</ArticleId><ArticleId IdType="pmc">PMC3684770</ArticleId><ArticleId IdType="pubmed">23608463</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinkova-Kostova AT, Kostov RV, Kazantsev AG. The role of Nrf2 signaling in counteracting neurodegenerative diseases. FEBS J. 2018;285:3576&#x2013;3590. doi: 10.1111/febs.14379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/febs.14379</ArticleId><ArticleId IdType="pmc">PMC6221096</ArticleId><ArticleId IdType="pubmed">29323772</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh T, et al. Carnosic acid, a catechol-type electrophilic compound, protects neurons both in vitro and in vivo through activation of the Keap1/Nrf2 pathway via S-alkylation of targeted cysteines on Keap1. J. Neurochem. 2008;104:1116&#x2013;1131. doi: 10.1111/j.1471-4159.2007.05039.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2007.05039.x</ArticleId><ArticleId IdType="pmc">PMC4566957</ArticleId><ArticleId IdType="pubmed">17995931</ArticleId></ArticleIdList></Reference><Reference><Citation>Satoh T, et al. Dual neuroprotective pathways of a pro-electrophilic compound via HSF-1-activated heat-shock proteins and Nrf2-activated phase 2 antioxidant response enzymes. J. Neurochem. 2011;119:569&#x2013;578. doi: 10.1111/j.1471-4159.2011.07449.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2011.07449.x</ArticleId><ArticleId IdType="pmc">PMC4580255</ArticleId><ArticleId IdType="pubmed">21883218</ArticleId></ArticleIdList></Reference><Reference><Citation>Mead, R. J., Shaw, P. J., Ogoe, C., Shan, N. &amp; Ferraiuolo, L. Treatment of neurological diseases. Patent PCT/US2019/056996 (2020).</Citation></Reference><Reference><Citation>Mead, R. J., Shaw, . J., Ogoe, C., Shan, N. &amp; Ferraiuolo, L. Treatment of neurological diseases. WO patent WO 2020/081973 A1 (2020).</Citation></Reference><Reference><Citation>Coya_Non-Confidential_Deck_2022.05.16 (Coya Therapeutics, 2022). https://coyatherapeutics.com</Citation></Reference><Reference><Citation>Zheng Q, Zhang S, Guo WZ, Li XK. The unique immunomodulatory properties of MSC-derived exosomes in organ transplantation. Front. Immunol. 2021;12:659621. doi: 10.3389/fimmu.2021.659621.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.659621</ArticleId><ArticleId IdType="pmc">PMC8055852</ArticleId><ArticleId IdType="pubmed">33889158</ArticleId></ArticleIdList></Reference><Reference><Citation>Thome AD, et al. Extracellular vesicles derived from ex vivo expanded regulatory T cells modulate in vitro and in vivo inflammation. Front. Immunol. 2022;13:875825. doi: 10.3389/fimmu.2022.875825.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.875825</ArticleId><ArticleId IdType="pmc">PMC9258040</ArticleId><ArticleId IdType="pubmed">35812435</ArticleId></ArticleIdList></Reference><Reference><Citation>De Cesco S, Davis JB, Brennan PE. TargetDB: a target information aggregation tool and tractability predictor. PLoS ONE. 2020;15:e0232644. doi: 10.1371/journal.pone.0232644.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0232644</ArticleId><ArticleId IdType="pmc">PMC7467329</ArticleId><ArticleId IdType="pubmed">32877430</ArticleId></ArticleIdList></Reference><Reference><Citation>Myszczynska MA, et al. Applications of machine learning to diagnosis and treatment of neurodegenerative diseases. Nat. Rev. Neurol. 2020;16:440&#x2013;456. doi: 10.1038/s41582-020-0377-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-020-0377-8</ArticleId><ArticleId IdType="pubmed">32669685</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith DP, et al. Expert-augmented computational drug repurposing identified baricitinib as a treatment for COVID-19. Front. Pharmacol. 2021;12:709856. doi: 10.3389/fphar.2021.709856.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.709856</ArticleId><ArticleId IdType="pmc">PMC8356560</ArticleId><ArticleId IdType="pubmed">34393789</ArticleId></ArticleIdList></Reference><Reference><Citation>Kariolis MS, et al. Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeys. Sci. Transl. Med. 2020;12:eaay1359. doi: 10.1126/scitranslmed.aay1359.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aay1359</ArticleId><ArticleId IdType="pubmed">32461332</ArticleId></ArticleIdList></Reference><Reference><Citation>Begley CG, et al. Drug repurposing: misconceptions, challenges, and opportunities for academic researchers. Sci. Transl. Med. 2021;13:eabd5524. doi: 10.1126/scitranslmed.abd5524.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abd5524</ArticleId><ArticleId IdType="pubmed">34550729</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatto N, et al. Directly converted astrocytes retain the ageing features of the donor fibroblasts and elucidate the astrocytic contribution to human CNS health and disease. Aging Cell. 2021;20:e13281. doi: 10.1111/acel.13281.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acel.13281</ArticleId><ArticleId IdType="pmc">PMC7811849</ArticleId><ArticleId IdType="pubmed">33314575</ArticleId></ArticleIdList></Reference><Reference><Citation>Stopford MJ, Allen SP, Ferraiuolo L. A high-throughput and pathophysiologically relevant astrocyte-motor neuron co-culture assay for amyotrophic lateral sclerosis therapeutic discovery. Bio. Protoc. 2019;9:e3353. doi: 10.21769/BioProtoc.3353.</Citation><ArticleIdList><ArticleId IdType="doi">10.21769/BioProtoc.3353</ArticleId><ArticleId IdType="pmc">PMC6774773</ArticleId><ArticleId IdType="pubmed">31579294</ArticleId></ArticleIdList></Reference><Reference><Citation>Braems E, Tziortzouda P, Van Den Bosch L. Exploring the alternative: fish, flies and worms as preclinical models for ALS. Neurosci. Lett. 2021;759:136041. doi: 10.1016/j.neulet.2021.136041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2021.136041</ArticleId><ArticleId IdType="pubmed">34118308</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Coyne AN, Lloyd TE. Drosophila models of amyotrophic lateral sclerosis with defects in RNA metabolism. Brain Res. 2018;1693:109&#x2013;120. doi: 10.1016/j.brainres.2018.04.043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2018.04.043</ArticleId><ArticleId IdType="pubmed">29752901</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaw MP, et al. Stable transgenic C9orf72 zebrafish model key aspects of the ALS/FTD phenotype and reveal novel pathological features. Acta Neuropathol. Commun. 2018;6:125. doi: 10.1186/s40478-018-0629-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-018-0629-7</ArticleId><ArticleId IdType="pmc">PMC6240957</ArticleId><ArticleId IdType="pubmed">30454072</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Berg LH, et al. Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials. Neurology. 2019;92:e1610&#x2013;e1623. doi: 10.1212/WNL.0000000000007242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007242</ArticleId><ArticleId IdType="pmc">PMC6448453</ArticleId><ArticleId IdType="pubmed">30850440</ArticleId></ArticleIdList></Reference><Reference><Citation>Verber N, Shaw PJ. Biomarkers in amyotrophic lateral sclerosis: a review of new developments. Curr. Opin. Neurol. 2020;33:662&#x2013;668. doi: 10.1097/WCO.0000000000000854.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WCO.0000000000000854</ArticleId><ArticleId IdType="pubmed">32796280</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M, et al. Evidence for an oligogenic basis of amyotrophic lateral sclerosis. Hum. Mol. Genet. 2012;21:3776&#x2013;3784. doi: 10.1093/hmg/dds199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/dds199</ArticleId><ArticleId IdType="pubmed">22645277</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournier CN, et al. Development and validation of the Rasch-built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) JAMA Neurol. 2020;77:480&#x2013;488. doi: 10.1001/jamaneurol.2019.4490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2019.4490</ArticleId><ArticleId IdType="pmc">PMC6990811</ArticleId><ArticleId IdType="pubmed">31886839</ArticleId></ArticleIdList></Reference><Reference><Citation>Balendra R, Al Khleifat A, Fang T, Al-Chalabi A. A standard operating procedure for King&#x2019;s ALS clinical staging. Amyotroph. Lateral Scler. Frontotemporal Degener. 2019;20:159&#x2013;164. doi: 10.1080/21678421.2018.1556696.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1556696</ArticleId><ArticleId IdType="pmc">PMC6558284</ArticleId><ArticleId IdType="pubmed">30773950</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, et al. Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone Study 19. J. Neurol. Neurosurg. Psychiatry. 2021;92:165&#x2013;171. doi: 10.1136/jnnp-2020-323271.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2020-323271</ArticleId><ArticleId IdType="pmc">PMC7841496</ArticleId><ArticleId IdType="pubmed">33109706</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng HJ, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17:423&#x2013;433. doi: 10.1016/S1474-4422(18)30089-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30089-9</ArticleId><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry JD, et al. Improved stratification of ALS clinical trials using predicted survival. Ann. Clin. Transl. Neurol. 2018;5:474&#x2013;485. doi: 10.1002/acn3.550.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.550</ArticleId><ArticleId IdType="pmc">PMC5899911</ArticleId><ArticleId IdType="pubmed">29687024</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, et al. Innovating clinical trials for amyotrophic lateral sclerosis: challenging the established order. Neurology. 2021;97:528&#x2013;536. doi: 10.1212/WNL.0000000000012545.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000012545</ArticleId><ArticleId IdType="pmc">PMC8456357</ArticleId><ArticleId IdType="pubmed">34315786</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, et al. An old friend who has overstayed their welcome: the ALSFRS-R total score as primary endpoint for ALS clinical trials. Amyotroph. Lateral Scler. Frontotemporal Degener. 2021;22:300&#x2013;307. doi: 10.1080/21678421.2021.1879865.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2021.1879865</ArticleId><ArticleId IdType="pubmed">33527843</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, et al. Adaptive platform trials to transform ALS therapy development. Ann. Neurol. 2022;91:165&#x2013;175. doi: 10.1002/ana.26285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.26285</ArticleId><ArticleId IdType="pubmed">34935174</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, et al. Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nat. Rev. Neurol. 2021;17:104&#x2013;118. doi: 10.1038/s41582-020-00434-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-020-00434-z</ArticleId><ArticleId IdType="pmc">PMC7747476</ArticleId><ArticleId IdType="pubmed">33340024</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutkove SB, et al. Improved ALS clinical trials through frequent at-home self-assessment: a proof of concept study. Ann. Clin. Transl. Neurol. 2020;7:1148&#x2013;1157. doi: 10.1002/acn3.51096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51096</ArticleId><ArticleId IdType="pmc">PMC7359124</ArticleId><ArticleId IdType="pubmed">32515889</ArticleId></ArticleIdList></Reference><Reference><Citation>Govindarajan R, Berry JD, Paganoni S, Pulley MT, Simmons Z. Optimizing telemedicine to facilitate amyotrophic lateral sclerosis clinical trials. Muscle Nerve. 2020;62:321&#x2013;326. doi: 10.1002/mus.26921.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26921</ArticleId><ArticleId IdType="pubmed">32415876</ArticleId></ArticleIdList></Reference><Reference><Citation>US Department of Health and Human Services. Adaptive designs for clinical trials of drugs and biologics: guidance for industry. FDAhttps://www.fda.gov/media/78495/download (2019).</Citation></Reference><Reference><Citation>Verber NS, et al. Biomarkers in motor neuron disease: a state of the art review. Front. Neurol. 2019;10:291. doi: 10.3389/fneur.2019.00291.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00291</ArticleId><ArticleId IdType="pmc">PMC6456669</ArticleId><ArticleId IdType="pubmed">31001186</ArticleId></ArticleIdList></Reference><Reference><Citation>Vissers M, Heuberger J, Groeneveld GJ. Targeting for success: demonstrating proof-of-concept with mechanistic early phase clinical pharmacology studies for disease-modification in neurodegenerative disorders. Int. J. Mol. Sci. 2021;22:1615. doi: 10.3390/ijms22041615.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22041615</ArticleId><ArticleId IdType="pmc">PMC7915613</ArticleId><ArticleId IdType="pubmed">33562713</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR, et al. A frequent ala 4 to val superoxide dismutase-1 mutation is associated with a rapidly progressive familial amyotrophic lateral sclerosis. Hum. Mol. Genet. 1994;3:981&#x2013;987. doi: 10.1093/hmg/3.6.981.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/3.6.981</ArticleId><ArticleId IdType="pubmed">7951249</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science. 1994;264:1772&#x2013;1775. doi: 10.1126/science.8209258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8209258</ArticleId><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott S, et al. Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph. Lateral Scler. 2008;9:4&#x2013;15. doi: 10.1080/17482960701856300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960701856300</ArticleId><ArticleId IdType="pubmed">18273714</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph AC, et al. Guidelines for preclinical animal research in ALS/MND: a consensus meeting. Amyotroph. Lateral Scler. 2010;11:38&#x2013;45. doi: 10.3109/17482960903545334.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960903545334</ArticleId><ArticleId IdType="pubmed">20184514</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner BJ, et al. TDP-43 expression in mouse models of amyotrophic lateral sclerosis and spinal muscular atrophy. BMC Neurosci. 2008;9:104. doi: 10.1186/1471-2202-9-104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2202-9-104</ArticleId><ArticleId IdType="pmc">PMC2583980</ArticleId><ArticleId IdType="pubmed">18957104</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, Fleck TJ, Himes CS, Hall ED. Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. Neurology. 1998;50:62&#x2013;66. doi: 10.1212/WNL.50.1.62.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.50.1.62</ArticleId><ArticleId IdType="pubmed">9443458</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito H, et al. Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Exp. Neurol. 2008;213:448&#x2013;455. doi: 10.1016/j.expneurol.2008.07.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2008.07.017</ArticleId><ArticleId IdType="pubmed">18718468</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319:1668&#x2013;1672. doi: 10.1126/science.1154584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1154584</ArticleId><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Petrucelli L. Rodent models of TDP-43 proteinopathy: investigating the mechanisms of TDP-43-mediated neurodegeneration. J. Mol. Neurosci. 2011;45:486&#x2013;499. doi: 10.1007/s12031-011-9610-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-011-9610-7</ArticleId><ArticleId IdType="pmc">PMC3207125</ArticleId><ArticleId IdType="pubmed">21811811</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu ZS. Does a loss of TDP-43 function cause neurodegeneration? Mol. Neurodegener. 2012;7:27. doi: 10.1186/1750-1326-7-27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-7-27</ArticleId><ArticleId IdType="pmc">PMC3419078</ArticleId><ArticleId IdType="pubmed">22697423</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold ES, et al. ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. Proc. Natl Acad. Sci. USA. 2013;110:E736&#x2013;E745. doi: 10.1073/pnas.1222809110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1222809110</ArticleId><ArticleId IdType="pmc">PMC3581922</ArticleId><ArticleId IdType="pubmed">23382207</ArticleId></ArticleIdList></Reference><Reference><Citation>Watkins JA, Alix JJP, Shaw PJ, Mead RJ. Extensive phenotypic characterisation of a human TDP-43(Q331K) transgenic mouse model of amyotrophic lateral sclerosis (ALS) Sci. Rep. 2021;11:16659. doi: 10.1038/s41598-021-96122-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-96122-z</ArticleId><ArticleId IdType="pmc">PMC8370970</ArticleId><ArticleId IdType="pubmed">34404845</ArticleId></ArticleIdList></Reference><Reference><Citation>White MA, et al. TDP-43 gains function due to perturbed autoregulation in a Tardbp knock-in mouse model of ALS-FTD. Nat. Neurosci. 2018;21:552&#x2013;563. doi: 10.1038/s41593-018-0113-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0113-5</ArticleId><ArticleId IdType="pmc">PMC5884423</ArticleId><ArticleId IdType="pubmed">29556029</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Z, et al. MRI-guided histology of TDP-43 knock-in mice implicates parvalbumin interneuron loss, impaired neurogenesis and aberrant neurodevelopment in amyotrophic lateral sclerosis-frontotemporal dementia. Brain Commun. 2021;3:fcab114. doi: 10.1093/braincomms/fcab114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcab114</ArticleId><ArticleId IdType="pmc">PMC8204366</ArticleId><ArticleId IdType="pubmed">34136812</ArticleId></ArticleIdList></Reference><Reference><Citation>Devoy A, et al. Humanized mutant FUS drives progressive motor neuron degeneration without aggregation in &#x2018;FUSDelta14&#x2019; knockin mice. Brain. 2017;140:2797&#x2013;2805. doi: 10.1093/brain/awx248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx248</ArticleId><ArticleId IdType="pmc">PMC5841203</ArticleId><ArticleId IdType="pubmed">29053787</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters OM, et al. Human C9ORF72 hexanucleotide expansion reproduces RNA foci and dipeptide repeat proteins but not neurodegeneration in BAC transgenic mice. Neuron. 2015;88:902&#x2013;909. doi: 10.1016/j.neuron.2015.11.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2015.11.018</ArticleId><ArticleId IdType="pmc">PMC4828340</ArticleId><ArticleId IdType="pubmed">26637797</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J, et al. Gain of toxicity from ALS/FTD-linked repeat expansions in C9ORF72 is alleviated by antisense oligonucleotides targeting GGGGCC-containing RNAs. Neuron. 2016;90:535&#x2013;550. doi: 10.1016/j.neuron.2016.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.04.006</ArticleId><ArticleId IdType="pmc">PMC4860075</ArticleId><ArticleId IdType="pubmed">27112497</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, et al. C9orf72 BAC mouse model with motor deficits and neurodegenerative features of ALS/FTD. Neuron. 2016;90:521&#x2013;534. doi: 10.1016/j.neuron.2016.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.04.005</ArticleId><ArticleId IdType="pubmed">27112499</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen L, et al. Survival and motor phenotypes in FVB C9-500 ALS/FTD BAC transgenic mice reproduced by multiple labs. Neuron. 2020;108:784&#x2013;796.e3. doi: 10.1016/j.neuron.2020.09.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2020.09.009</ArticleId><ArticleId IdType="pmc">PMC8281452</ArticleId><ArticleId IdType="pubmed">33022226</ArticleId></ArticleIdList></Reference><Reference><Citation>Mordes DA, et al. Absence of survival and motor deficits in 500 repeat C9ORF72 BAC mice. Neuron. 2020;108:775&#x2013;783.e4. doi: 10.1016/j.neuron.2020.08.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2020.08.009</ArticleId><ArticleId IdType="pubmed">33022228</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraiuolo L, Maragakis NJ. Mini-review: induced pluripotent stem cells and the search for new cell-specific ALS therapeutic targets. Neurosci. Lett. 2021;755:135911. doi: 10.1016/j.neulet.2021.135911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2021.135911</ArticleId><ArticleId IdType="pubmed">33892003</ArticleId></ArticleIdList></Reference><Reference><Citation>Imamura K, et al. The Src/c-Abl pathway is a potential therapeutic target in amyotrophic lateral sclerosis. Sci. Transl. Med. 2017;9:aaf3962. doi: 10.1126/scitranslmed.aaf3962.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaf3962</ArticleId><ArticleId IdType="pubmed">28539470</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujimori K, et al. Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent. Nat. Med. 2018;24:1579&#x2013;1589. doi: 10.1038/s41591-018-0140-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0140-5</ArticleId><ArticleId IdType="pubmed">30127392</ArticleId></ArticleIdList></Reference><Reference><Citation>Boillee S, Vande Velde C, Cleveland DW. ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron. 2006;52:39&#x2013;59. doi: 10.1016/j.neuron.2006.09.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2006.09.018</ArticleId><ArticleId IdType="pubmed">17015226</ArticleId></ArticleIdList></Reference><Reference><Citation>Lapasset L, et al. Rejuvenating senescent and centenarian human cells by reprogramming through the pluripotent state. Genes Dev. 2011;25:2248&#x2013;2253. doi: 10.1101/gad.173922.111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.173922.111</ArticleId><ArticleId IdType="pmc">PMC3219229</ArticleId><ArticleId IdType="pubmed">22056670</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira JD, et al. Human sensorimotor organoids derived from healthy and amyotrophic lateral sclerosis stem cells form neuromuscular junctions. Nat. Commun. 2021;12:4744. doi: 10.1038/s41467-021-24776-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-24776-4</ArticleId><ArticleId IdType="pmc">PMC8346474</ArticleId><ArticleId IdType="pubmed">34362895</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan S, et al. A comprehensive analysis of rare genetic variation in amyotrophic lateral sclerosis in the UK. Brain. 2017;140:1611&#x2013;1618. doi: 10.1093/brain/awx082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx082</ArticleId><ArticleId IdType="pmc">PMC5445258</ArticleId><ArticleId IdType="pubmed">28430856</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J, et al. Targeted genetic screen in amyotrophic lateral sclerosis reveals novel genetic variants with synergistic effect on clinical phenotype. Front. Mol. Neurosci. 2017;10:370. doi: 10.3389/fnmol.2017.00370.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00370</ArticleId><ArticleId IdType="pmc">PMC5684183</ArticleId><ArticleId IdType="pubmed">29170628</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Ou R, Wei Q, Shang H. Shared genetic links between amyotrophic lateral sclerosis and obesity-related traits: a genome-wide association study. Neurobiol. Aging. 2021;102:211.e1&#x2013;211.e9. doi: 10.1016/j.neurobiolaging.2021.01.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2021.01.023</ArticleId><ArticleId IdType="pubmed">33640203</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling JP, Pletnikova O, Troncoso JC, Wong PC. TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science. 2015;349:650&#x2013;655. doi: 10.1126/science.aab0983.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aab0983</ArticleId><ArticleId IdType="pmc">PMC4825810</ArticleId><ArticleId IdType="pubmed">26250685</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudencio M, et al. Truncated stathmin-2 is a marker of TDP-43 pathology in frontotemporal dementia. J. Clin. Invest. 2020;130:6080&#x2013;6092. doi: 10.1172/JCI139741.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI139741</ArticleId><ArticleId IdType="pmc">PMC7598060</ArticleId><ArticleId IdType="pubmed">32790644</ArticleId></ArticleIdList></Reference><Reference><Citation>Elden AC, et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature. 2010;466:1069&#x2013;1075. doi: 10.1038/nature09320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09320</ArticleId><ArticleId IdType="pmc">PMC2965417</ArticleId><ArticleId IdType="pubmed">20740007</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith BN, et al. Mutations in the vesicular trafficking protein annexin A11 are associated with amyotrophic lateral sclerosis. Sci. Transl. Med. 2017;9:eaad9157. doi: 10.1126/scitranslmed.aad9157.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aad9157</ArticleId><ArticleId IdType="pmc">PMC6599403</ArticleId><ArticleId IdType="pubmed">28469040</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J, et al. Rare variant burden analysis within enhancers identifies CAV1 as an ALS risk gene. Cell Rep. 2020;33:108456. doi: 10.1016/j.celrep.2020.108456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.108456</ArticleId><ArticleId IdType="pmc">PMC7710676</ArticleId><ArticleId IdType="pubmed">33264630</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J, et al. Mutations in the glycosyltransferase domain of GLT8D1 are associated with familial amyotrophic lateral sclerosis. Cell Rep. 2019;26:2298&#x2013;2306.e5. doi: 10.1016/j.celrep.2019.02.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2019.02.006</ArticleId><ArticleId IdType="pmc">PMC7003067</ArticleId><ArticleId IdType="pubmed">30811981</ArticleId></ArticleIdList></Reference><Reference><Citation>Farhan SMK, et al. Exome sequencing in amyotrophic lateral sclerosis implicates a novel gene, DNAJC7, encoding a heat-shock protein. Nat. Neurosci. 2019;22:1966&#x2013;1974. doi: 10.1038/s41593-019-0530-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-019-0530-0</ArticleId><ArticleId IdType="pmc">PMC6919277</ArticleId><ArticleId IdType="pubmed">31768050</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohassel P, et al. Childhood amyotrophic lateral sclerosis caused by excess sphingolipid synthesis. Nat. Med. 2021;27:1197&#x2013;1204. doi: 10.1038/s41591-021-01346-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01346-1</ArticleId><ArticleId IdType="pmc">PMC9309980</ArticleId><ArticleId IdType="pubmed">34059824</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson JO, et al. Association of variants in the SPTLC1 gene with juvenile amyotrophic lateral sclerosis. JAMA Neurol. 2021;78:1236&#x2013;1248. doi: 10.1001/jamaneurol.2021.2598.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2021.2598</ArticleId><ArticleId IdType="pmc">PMC8406220</ArticleId><ArticleId IdType="pubmed">34459874</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura R, et al. A multi-ethnic meta-analysis identifies novel genes, including ACSL5, associated with amyotrophic lateral sclerosis. Commun. Biol. 2020;3:526. doi: 10.1038/s42003-020-01251-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-020-01251-2</ArticleId><ArticleId IdType="pmc">PMC7511394</ArticleId><ArticleId IdType="pubmed">32968195</ArticleId></ArticleIdList></Reference><Reference><Citation>Iacoangeli A, et al. Genome-wide meta-analysis finds the ACSL5-ZDHHC6 locus is associated with ALS and links weight loss to the disease genetics. Cell Rep. 2020;33:108323. doi: 10.1016/j.celrep.2020.108323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.108323</ArticleId><ArticleId IdType="pmc">PMC7610013</ArticleId><ArticleId IdType="pubmed">33113361</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt A, et al. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat. Neurosci. 2015;18:631&#x2013;636. doi: 10.1038/nn.4000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4000</ArticleId><ArticleId IdType="pubmed">25803835</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenna KP, et al. NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. Nat. Genet. 2016;48:1037&#x2013;1042. doi: 10.1038/ng.3626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3626</ArticleId><ArticleId IdType="pmc">PMC5560030</ArticleId><ArticleId IdType="pubmed">27455347</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow CY, et al. Deleterious variants of FIG4, a phosphoinositide phosphatase, in patients with ALS. Am. J. Hum. Genet. 2009;84:85&#x2013;88. doi: 10.1016/j.ajhg.2008.12.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2008.12.010</ArticleId><ArticleId IdType="pmc">PMC2668033</ArticleId><ArticleId IdType="pubmed">19118816</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendell JR, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N. Engl. J. Med. 2017;377:1713&#x2013;1722. doi: 10.1056/NEJMoa1706198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1706198</ArticleId><ArticleId IdType="pubmed">29091557</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, et al. Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis. Sci. Transl. Med. 2017;9:eaai7866. doi: 10.1126/scitranslmed.aai7866.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aai7866</ArticleId><ArticleId IdType="pmc">PMC5576451</ArticleId><ArticleId IdType="pubmed">28356511</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, et al. Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology. 2020;95:e59&#x2013;e69. doi: 10.1212/WNL.0000000000009559.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000009559</ArticleId><ArticleId IdType="pmc">PMC7371380</ArticleId><ArticleId IdType="pubmed">32385188</ArticleId></ArticleIdList></Reference><Reference><Citation>Zucchi E, et al. Neurofilaments in motor neuron disorders: towards promising diagnostic and prognostic biomarkers. Mol. Neurodegener. 2020;15:58. doi: 10.1186/s13024-020-00406-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-00406-3</ArticleId><ArticleId IdType="pmc">PMC7559190</ArticleId><ArticleId IdType="pubmed">33059698</ArticleId></ArticleIdList></Reference><Reference><Citation>Poesen K, Van Damme P. Diagnostic and prognostic performance of neurofilaments in ALS. Front. Neurol. 2018;9:1167. doi: 10.3389/fneur.2018.01167.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.01167</ArticleId><ArticleId IdType="pmc">PMC6345692</ArticleId><ArticleId IdType="pubmed">30713520</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu CH, et al. Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology. 2015;84:2247&#x2013;2257. doi: 10.1212/WNL.0000000000001642.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001642</ArticleId><ArticleId IdType="pmc">PMC4456658</ArticleId><ArticleId IdType="pubmed">25934855</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu CH, et al. Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study. J. Neurol. Neurosurg. Psychiatry. 2015;86:565&#x2013;573. doi: 10.1136/jnnp-2014-307672.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2014-307672</ArticleId><ArticleId IdType="pmc">PMC4413806</ArticleId><ArticleId IdType="pubmed">25009280</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto H, Brooks BR, Silani V. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol. 2014;13:1127&#x2013;1138. doi: 10.1016/S1474-4422(14)70129-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70129-2</ArticleId><ArticleId IdType="pubmed">25316019</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, et al. Trial of celecoxib in amyotrophic lateral sclerosis. Ann. Neurol. 2006;60:22&#x2013;31. doi: 10.1002/ana.20903.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20903</ArticleId><ArticleId IdType="pubmed">16802291</ArticleId></ArticleIdList></Reference><Reference><Citation>Forgrave LM, Ma M, Best JR, DeMarco ML. The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer&#x2019;s disease, frontotemporal dementia, and amyotrophic lateral sclerosis: a systematic review and meta-analysis. Alzheimers Dement. 2019;11:730&#x2013;743.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6939029</ArticleId><ArticleId IdType="pubmed">31909174</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagliardi D, et al. Diagnostic and prognostic role of blood and cerebrospinal fluid and blood neurofilaments in amyotrophic lateral sclerosis: a review of the literature. Int. J. Mol. Sci. 2019;20:4152. doi: 10.3390/ijms20174152.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20174152</ArticleId><ArticleId IdType="pmc">PMC6747516</ArticleId><ArticleId IdType="pubmed">31450699</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson AG, et al. Multicentre appraisal of amyotrophic lateral sclerosis biofluid biomarkers shows primacy of blood neurofilament light chain. Brain Commun. 2022;4:fcac029. doi: 10.1093/braincomms/fcac029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/braincomms/fcac029</ArticleId><ArticleId IdType="pmc">PMC8870425</ArticleId><ArticleId IdType="pubmed">35224491</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, Andersen PM, Lombardi V, Malaspina A. Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann. Neurol. 2018;84:130&#x2013;139. doi: 10.1002/ana.25276.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25276</ArticleId><ArticleId IdType="pubmed">30014505</ArticleId></ArticleIdList></Reference><Reference><Citation>Magen I, et al. Circulating miR-181 is a prognostic biomarker for amyotrophic lateral sclerosis. Nat. Neurosci. 2021;24:1534&#x2013;1541. doi: 10.1038/s41593-021-00936-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-021-00936-z</ArticleId><ArticleId IdType="pubmed">34711961</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuwirth C, et al. Tracking motor neuron loss in a set of six muscles in amyotrophic lateral sclerosis using the Motor Unit Number Index (MUNIX): a 15-month longitudinal multicentre trial. J. Neurol. Neurosurg. Psychiatry. 2015;86:1172&#x2013;1179. doi: 10.1136/jnnp-2015-310509.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-310509</ArticleId><ArticleId IdType="pubmed">25935892</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto S, de Carvalho M. Symmetry of phrenic nerve motor response in amyotrophic lateral sclerosis. Muscle Nerve. 2010;42:822&#x2013;825. doi: 10.1002/mus.21816.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.21816</ArticleId><ArticleId IdType="pubmed">20928909</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M, et al. A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 2010;11:456&#x2013;460. doi: 10.3109/17482968.2010.498521.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2010.498521</ArticleId><ArticleId IdType="pubmed">20565333</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellis CM, et al. A proton magnetic resonance spectroscopic study in ALS: correlation with clinical findings. Neurology. 1998;51:1104&#x2013;1109. doi: 10.1212/WNL.51.4.1104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.51.4.1104</ArticleId><ArticleId IdType="pubmed">9781537</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagani M, et al. Functional pattern of brain FDG-PET in amyotrophic lateral sclerosis. Neurology. 2014;83:1067&#x2013;1074. doi: 10.1212/WNL.0000000000000792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000792</ArticleId><ArticleId IdType="pubmed">25122207</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vocht J, et al. Use of multimodal imaging and clinical biomarkers in presymptomatic carriers of C9orf72 repeat expansion. JAMA Neurol. 2020;77:1008&#x2013;1017. doi: 10.1001/jamaneurol.2020.1087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.1087</ArticleId><ArticleId IdType="pmc">PMC7417970</ArticleId><ArticleId IdType="pubmed">32421156</ArticleId></ArticleIdList></Reference><Reference><Citation>Zurcher NR, et al. Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: assessed with [11C]-PBR28. Neuroimage Clin. 2015;7:409&#x2013;414. doi: 10.1016/j.nicl.2015.01.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2015.01.009</ArticleId><ArticleId IdType="pmc">PMC4310932</ArticleId><ArticleId IdType="pubmed">25685708</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikawa M, Okazawa H, Nakamoto Y, Yoneda M. PET imaging for oxidative stress in neurodegenerative disorders associated with mitochondrial dysfunction. Antioxidants. 2020;9:861. doi: 10.3390/antiox9090861.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox9090861</ArticleId><ArticleId IdType="pmc">PMC7554831</ArticleId><ArticleId IdType="pubmed">32937849</ArticleId></ArticleIdList></Reference><Reference><Citation>Malpetti M, et al. Synaptic density in carriers of C9orf72 mutations: a [11C]UCB-J PET study. Ann. Clin. Transl. Neurol. 2021;8:1515&#x2013;1523. doi: 10.1002/acn3.51407.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51407</ArticleId><ArticleId IdType="pmc">PMC8283163</ArticleId><ArticleId IdType="pubmed">34133849</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>